PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 26041923-7 2015 Together, these data indicate that functional upregulation of alpha4* nAChRs in VTA GABAergic neurons confers increased sensitivity to nicotine reward and points to nAChR subtypes specifically expressed in GABAergic VTA neurons as molecular targets for smoking cessation therapeutics. Nicotine 135-143 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 70-75 24750355-2 2015 Here, we utilize genetic and pharmacological tools to further investigate the nicotinic acetylcholine receptor (nAChR) subtypes that support intravenous self-administration of nicotine. Nicotine 176-184 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 78-110 25948261-9 2015 Furthermore, at E12.5 we found evidence for unconventional receptors that were responsive to the nAChR agonists 1-dimethyl-4-phenylpiperazinium and nicotine, but were insensitive to the general nicotinic blocker, hexamethonium. Nicotine 148-156 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 97-102 24750355-2 2015 Here, we utilize genetic and pharmacological tools to further investigate the nicotinic acetylcholine receptor (nAChR) subtypes that support intravenous self-administration of nicotine. Nicotine 176-184 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 112-117 25430056-5 2015 Nicotine induced dose- and time-dependent upregulation of IP3 R-1 protein following its mRNA increase, and the latter was significantly suppressed by a nonselective nicotinic acetylcholine receptors (nAChR) antagonist, mecamylamine. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 165-198 25430056-8 2015 These results indicate that nAChR activation by nicotine upregulates IP3 R-1 via increase of activator protein-1, which is a cFos and cJun dimmer, in the nucleus, with activation of Ca(2+) signaling transduction processes. Nicotine 48-56 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 28-33 25430056-5 2015 Nicotine induced dose- and time-dependent upregulation of IP3 R-1 protein following its mRNA increase, and the latter was significantly suppressed by a nonselective nicotinic acetylcholine receptors (nAChR) antagonist, mecamylamine. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 200-205 26351626-1 2015 Our previous studies showed that alpha7 nicotinic acetylcholine receptor (nAchR) agonist nicotine has stimulatory effects on murine bone marrow-derived semimature DCs, but the effect of nicotine on peripheral blood mononuclear cell- (PBMC-) derived human semimature dendritic cells (hu-imDCs) is still to be clarified. Nicotine 89-97 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 74-79 25740504-8 2015 Chronic exposure to nicotine selectively affects alpha4beta2 nAChRs in STN: this treatment increased the number of alpha4beta2 neurons, upregulated alpha4-containing nAChR number and sensitivity, and enhanced the basal firing rate of alpha4beta2 neurons both ex vivo and in vivo. Nicotine 20-28 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 61-66 25560939-8 2015 While these beta4*-nAChR sites were generally resistant to regulation by chronic nicotine treatment, significant increases in binding were noted for habenula and hindbrain. Nicotine 81-89 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 19-24 26351626-1 2015 Our previous studies showed that alpha7 nicotinic acetylcholine receptor (nAchR) agonist nicotine has stimulatory effects on murine bone marrow-derived semimature DCs, but the effect of nicotine on peripheral blood mononuclear cell- (PBMC-) derived human semimature dendritic cells (hu-imDCs) is still to be clarified. Nicotine 186-194 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 74-79 25381636-0 2015 Nicotine-induced upregulation of VCAM-1, MMP-2, and MMP-9 through the alpha7-nAChR-JNK pathway in RAW264.7 and MOVAS cells. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 70-82 25381636-7 2015 Furthermore, the nicotine exposure equivalent to plasma levels found in regular smokers can augment VCAM-1, MMP-2, and MMP-9 expressions through the alpha7-nAChR-JNK pathway. Nicotine 17-25 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 149-161 25381636-4 2015 When cells were pretreated with either SP600125 (JNK inhibitor) or PNU-282987 (alpha7-nAChR agonist) prior to nicotine exposure, the nicotine-induced upregulation of VCAM-1, MMP-2, MMP-9, and p-JNK was suppressed, with a joint treatment producing a more significant inhibitory effect. Nicotine 110-118 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 79-91 25381636-4 2015 When cells were pretreated with either SP600125 (JNK inhibitor) or PNU-282987 (alpha7-nAChR agonist) prior to nicotine exposure, the nicotine-induced upregulation of VCAM-1, MMP-2, MMP-9, and p-JNK was suppressed, with a joint treatment producing a more significant inhibitory effect. Nicotine 133-141 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 79-91 25447802-4 2015 The use of new technologies (including optogenetics) and the development of mouse models characterised by cell-specific deletions of receptor subtype genes or the expression of gain-of-function nAChR subunits has greatly increased our understanding of the molecular mechanisms and neural substrates of nicotine addiction first revealed by classic electrophysiological, neurochemical and behavioural approaches. Nicotine 302-310 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 194-199 24800895-11 2014 Differential substitution for the nicotine discriminative stimulus is consistent with differences in alpha4beta2 nAChR efficacy; however, collectively the current results suggest that multiple nAChR receptor subtypes mediate the effects of the agonists. Nicotine 34-42 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 113-118 25344397-7 2014 In addition, the miRNAs that target nAChR 3" UTRs are expressed in mouse brain and are regulated by chronic nicotine exposure. Nicotine 108-116 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 36-41 25046735-7 2014 This nicotine effect was mediated by the activation of non-alpha7 nAChR subtypes, which were not activated by ACh released during LTD-inducing stimulation, and requires the presence of endogenous ACh-induced alpha7 nAChR activation. Nicotine 5-13 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 59-65 25258409-11 2014 These results demonstrate that nicotine suppresses acute colitis and colitis-associated tumorigenesis, and this effect may be associated with the activation of alpha7-nAChR. Nicotine 31-39 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 160-172 25651617-1 2014 Nicotine (NIC) regulates various cellular functions acting on the nicotinic acetylcholine receptor (nAChR). Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 66-98 25651617-1 2014 Nicotine (NIC) regulates various cellular functions acting on the nicotinic acetylcholine receptor (nAChR). Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 100-105 25651617-1 2014 Nicotine (NIC) regulates various cellular functions acting on the nicotinic acetylcholine receptor (nAChR). Nicotine 10-13 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 66-98 25651617-1 2014 Nicotine (NIC) regulates various cellular functions acting on the nicotinic acetylcholine receptor (nAChR). Nicotine 10-13 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 100-105 25651617-7 2014 Moreover, NIC-induced antinociception was antagonized by both alpha 4 beta 2 and alpha 7 nAChR antagonists, while NIC-induced HPA axis activation was antagonized by alpha 4 beta 2 nAChR antagonist, but not by alpha 7 nAChR antagonist. Nicotine 10-13 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 81-94 25651617-7 2014 Moreover, NIC-induced antinociception was antagonized by both alpha 4 beta 2 and alpha 7 nAChR antagonists, while NIC-induced HPA axis activation was antagonized by alpha 4 beta 2 nAChR antagonist, but not by alpha 7 nAChR antagonist. Nicotine 10-13 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 89-94 25046735-7 2014 This nicotine effect was mediated by the activation of non-alpha7 nAChR subtypes, which were not activated by ACh released during LTD-inducing stimulation, and requires the presence of endogenous ACh-induced alpha7 nAChR activation. Nicotine 5-13 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 208-214 25046735-7 2014 This nicotine effect was mediated by the activation of non-alpha7 nAChR subtypes, which were not activated by ACh released during LTD-inducing stimulation, and requires the presence of endogenous ACh-induced alpha7 nAChR activation. Nicotine 5-13 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 215-220 25258409-6 2014 Nicotine and a selective agonist of the alpha7-nicotinic acetylcholine receptor (alpha7-nAChR) reduced the severity of DSS-induced acute colonic inflammation. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 40-79 25258409-6 2014 Nicotine and a selective agonist of the alpha7-nicotinic acetylcholine receptor (alpha7-nAChR) reduced the severity of DSS-induced acute colonic inflammation. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 81-93 25258409-7 2014 In addition, the suppressive effect of nicotine on acute colitis was attenuated by an antagonist of alpha7-nAChR. Nicotine 39-47 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 100-112 25396421-11 2014 Because nicotine is a alpha7nAchR agonist and methyllycaconitine is a alpha7nAchR antagonist, we conclude that alpha7nAchR activation increases the phosphorylation of STAT3, reduces the expression of TNF-alpha and IL-6, and, ultimately, alleviates viral myocarditis. Nicotine 8-16 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 22-33 25028511-8 2014 EC50 values for nicotine acting at malpha6mbeta4*-nAChR were unaffected by beta3 subunit residue substitutions in loop C or E. Thus, amino acid residues located in primary (loop C) or complementary (loops beta2-beta3 and E) interfaces of beta3 subunits are some of the molecular impediments for functional expression of malpha6mbeta2beta3- or malpha6mbeta4beta3-nAChRs. Nicotine 16-24 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 50-55 25296021-4 2014 METHODS: Primary lung fibroblasts isolated from wild type and alpha7 nicotinic acetylcholine receptor (alpha7 nAChR) deficient mice were treated with nicotine (50 microg/ml) in vitro for 72 hours. Nicotine 150-158 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 62-101 25296021-12 2014 CONCLUSION: Nicotine stimulates NGF release by lung fibroblasts through alpha7 nAChR and NFkappaB dependent pathways. Nicotine 12-20 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 72-84 25296021-13 2014 These novel findings suggest that the nicotine-alpha7 nAChR-NFkappaB- NGF axis may provide novel therapeutic targets to attenuate tobacco smoke-induced AHR. Nicotine 38-46 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 47-59 25051446-7 2014 Chronic nicotine treatment significantly suppressed expression of alpha3-nAChR (predominant peripheral alpha-subunit) in liver. Nicotine 8-16 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 73-78 25051446-13 2014 Chronic nicotine treatment enhanced PI-3-kinase activities and increased Akt and glycogen synthase kinase (GSK)-3beta phosphorylation in an nAChR-dependent manner coupled with decreased cAMP response element-binding protein (CREB) phosphorylation. Nicotine 8-16 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 140-145 25046735-7 2014 This nicotine effect was mediated by the activation of non-alpha7 nAChR subtypes, which were not activated by ACh released during LTD-inducing stimulation, and requires the presence of endogenous ACh-induced alpha7 nAChR activation. Nicotine 5-13 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 66-71 24298024-3 2014 We examined the antiinflammatory effect of nicotine, a potent alpha7 nicotinic acetylcholine receptor (alpha7nAChR) agonist, with regard to TLR expression and signaling during sepsis. Nicotine 43-51 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 62-101 25038610-6 2014 Mice pre-exposed to nicotine had upregulated alpha4YFP nAChR subunits in the hippocampal medial perforant path and on ventral tegmental area GABAergic neurons as compared to chronic saline mice. Nicotine 20-28 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 55-60 25038610-8 2014 CONCLUSIONS: Chronic forced pre-exposure of nicotine is sufficient to induce elevated oral nicotine intake and supports the postulate that nAChR upregulation may be a key factor influencing nicotine self-administration. Nicotine 44-52 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 139-144 25038610-8 2014 CONCLUSIONS: Chronic forced pre-exposure of nicotine is sufficient to induce elevated oral nicotine intake and supports the postulate that nAChR upregulation may be a key factor influencing nicotine self-administration. Nicotine 91-99 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 139-144 25038610-8 2014 CONCLUSIONS: Chronic forced pre-exposure of nicotine is sufficient to induce elevated oral nicotine intake and supports the postulate that nAChR upregulation may be a key factor influencing nicotine self-administration. Nicotine 91-99 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 139-144 25038610-2 2014 In this study, we examined whether mice pretreated with chronic nicotine, at a dosing regimen that results in maximal nicotinic acetylcholine receptor (nAChR) upregulation, would display evidence of nicotine-dependent behaviour during nicotine self-administration. Nicotine 64-72 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 118-150 25038610-2 2014 In this study, we examined whether mice pretreated with chronic nicotine, at a dosing regimen that results in maximal nicotinic acetylcholine receptor (nAChR) upregulation, would display evidence of nicotine-dependent behaviour during nicotine self-administration. Nicotine 64-72 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 152-157 25038610-2 2014 In this study, we examined whether mice pretreated with chronic nicotine, at a dosing regimen that results in maximal nicotinic acetylcholine receptor (nAChR) upregulation, would display evidence of nicotine-dependent behaviour during nicotine self-administration. Nicotine 199-207 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 152-157 25038610-2 2014 In this study, we examined whether mice pretreated with chronic nicotine, at a dosing regimen that results in maximal nicotinic acetylcholine receptor (nAChR) upregulation, would display evidence of nicotine-dependent behaviour during nicotine self-administration. Nicotine 199-207 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 152-157 24661093-10 2014 This study examined dose-response relationships for murine alpha6beta2*-nicotinic acetylcholine receptor (nAChR) down-regulation by chronic nicotine treatment. Nicotine 140-148 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 59-104 24661093-10 2014 This study examined dose-response relationships for murine alpha6beta2*-nicotinic acetylcholine receptor (nAChR) down-regulation by chronic nicotine treatment. Nicotine 140-148 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 106-111 24811002-0 2014 Antimuscle atrophy effect of nicotine targets muscle satellite cells partly through an alpha7 nicotinic receptor in a murine hindlimb ischemia model. Nicotine 29-37 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 87-112 24811002-6 2014 Such effects of nicotine were attenuated in alpha7 nicotinic receptor knockout mice. Nicotine 16-24 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 44-69 24298024-3 2014 We examined the antiinflammatory effect of nicotine, a potent alpha7 nicotinic acetylcholine receptor (alpha7nAChR) agonist, with regard to TLR expression and signaling during sepsis. Nicotine 43-51 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 103-114 24289814-0 2014 Genetic variation within the Chrna7 gene modulates nicotine reward-like phenotypes in mice. Nicotine 51-59 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 29-35 24289814-2 2014 Genetic analysis of gene expression and behavior identified Chrna7 as potentially modulating nicotine place conditioning in the BXD panel of inbred mice. Nicotine 93-101 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 60-66 24289814-3 2014 We used gene targeting and pharmacological tools to confirm the role of Chrna7 in nicotine conditioned place preference (CPP). Nicotine 82-90 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 72-78 24289814-5 2014 In the BXD panel, we found a putative cis expression quantitative trait loci (eQTL) for Chrna7 in NAc that correlated inversely to nicotine CPP. Nicotine 131-139 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 88-94 24289814-7 2014 In B6 mice, the alpha7 nicotinic acetylcholine receptor (nAChR)-selective agonist, PHA-543613, dose-dependently blocked nicotine CPP, which was restored using the alpha7 nAChR-selective antagonist, methyllycaconitine citrate (MLA). Nicotine 120-128 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 57-62 24289814-7 2014 In B6 mice, the alpha7 nicotinic acetylcholine receptor (nAChR)-selective agonist, PHA-543613, dose-dependently blocked nicotine CPP, which was restored using the alpha7 nAChR-selective antagonist, methyllycaconitine citrate (MLA). Nicotine 120-128 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 170-175 24289814-9 2014 Mice lacking Chrna7 demonstrate increased insulin signaling in the NAc, which may modulate nicotine place preference. Nicotine 91-99 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 13-19 24055499-6 2014 In vivo chronic nicotine exposure during development significantly modified apical dendrite morphology and nAChR currents, compared with vehicle control. Nicotine 16-24 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 107-112 24055499-8 2014 Surprisingly, neurons from wildtype mice treated with in vivo nicotine resembled those from alpha5(-/-) mice treated with vehicle, maintaining into adulthood a morphological phenotype characteristic of immature mice together with reduced nAChR currents. Nicotine 62-70 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 238-243 24055499-9 2014 In alpha5(-/-) mice, however, developmental in vivo nicotine tended to normalize both adult morphology and nAChR currents. Nicotine 52-60 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 107-112 24055499-11 2014 In wildtype mice, the lasting alterations to the morphology and nAChR activation of prefrontal layer VI neurons are teratogenic changes consistent with the attention deficits observed following developmental nicotine exposure. Nicotine 208-216 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 64-69 24349346-5 2013 The sustained phase of the nicotine-induced Ca(2+) response was blocked by alpha-BgTx but not by DHbetaE and was mimicked by alpha7*nAChR agonists but not by non-alpha7*nAChR agonists. Nicotine 27-35 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 125-137 24349346-5 2013 The sustained phase of the nicotine-induced Ca(2+) response was blocked by alpha-BgTx but not by DHbetaE and was mimicked by alpha7*nAChR agonists but not by non-alpha7*nAChR agonists. Nicotine 27-35 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 162-174 24349346-8 2013 In conclusion, activation of presynaptic nAChRs by nicotine elicits Ca(2+) influx into the presynaptic axons, the sustained phase of the nicotine-induced Ca(2+) response requires that axonal alpha7*nAChR activate a downstream signaling network in the vHipp axons. Nicotine 137-145 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 191-203 23926288-0 2013 Bimodal concentration-response of nicotine involves the nicotinic acetylcholine receptor, transient receptor potential vanilloid type 1, and transient receptor potential ankyrin 1 channels in mouse trachea and sensory neurons. Nicotine 34-42 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 56-88 24223920-14 2013 The data suggest that the beta2 subunit of the nAChR is critically involved in the nicotine-induced inhibition of these resident macrophages. Nicotine 83-91 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 47-52 23583933-0 2013 Genetic deletion of the adenosine A(2A) receptor prevents nicotine-induced upregulation of alpha7, but not alpha4beta2* nicotinic acetylcholine receptor binding in the brain. Nicotine 58-66 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 120-152 23747348-4 2013 A significant inverse correlation between the locomotor and hypothermic effects and the density of nicotine binding sites suggested that differential expression alpha4beta2-neuronal nicotinic acetylcholine receptor (nAChR) mediated some of this genetic variability. Nicotine 99-107 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 182-214 23747348-4 2013 A significant inverse correlation between the locomotor and hypothermic effects and the density of nicotine binding sites suggested that differential expression alpha4beta2-neuronal nicotinic acetylcholine receptor (nAChR) mediated some of this genetic variability. Nicotine 99-107 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 216-221 23747348-6 2013 However, null mutant mice still respond to nicotine, indicating that other nAChR subtypes also mediate these responses. Nicotine 43-51 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 75-80 23747348-9 2013 While genetic variability in nAChR expression and function is an important factor contributing to differences in response to nicotine, the observations that altered activity of opioid, glutamate, and cannabinoid receptors among others also change nicotine sensitivity reinforces the proposal that the genetics of nicotine response is more complex than differences in nAChRs. Nicotine 125-133 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 29-34 23811312-3 2013 Recent evidence indicates that nicotinic acetylcholine receptors (nAChRs), ligand-gated cation channels activated by ACh and nicotine, may contribute to ethanol-mediated activation of VTA DAergic neurons although the nAChR subtype(s) involved has not been fully elucidated. Nicotine 125-133 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 66-71 23831952-9 2013 In contrast to the studies with alpha4 and alpha6 knockout mice, nicotine treatment did reduce L-dopa-induced AIMs in parkinsonian alpha7 nAChR knockout mice. Nicotine 65-73 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 131-143 23842742-3 2013 Herein, we report that nicotine, an unselective alpha7-nAChR agonist, protects from morphological and synaptic impairments induced by Abeta oligomers. Nicotine 23-31 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 48-60 23842742-5 2013 On the other hand, a cross-talk between alpha7-nAChR and the Wnt/beta-catenin signaling pathway was revealed by the following facts: (1) nicotine stabilizes beta-catenin, in a concentration-dependent manner; (2) nicotine prevents Abeta-induced loss of beta-catenin through the alpha7-nAChR; and (3) activation of canonical Wnt/beta-catenin signaling induces alpha7-nAChR expression. Nicotine 137-145 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 40-52 23842742-5 2013 On the other hand, a cross-talk between alpha7-nAChR and the Wnt/beta-catenin signaling pathway was revealed by the following facts: (1) nicotine stabilizes beta-catenin, in a concentration-dependent manner; (2) nicotine prevents Abeta-induced loss of beta-catenin through the alpha7-nAChR; and (3) activation of canonical Wnt/beta-catenin signaling induces alpha7-nAChR expression. Nicotine 137-145 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 277-289 23842742-5 2013 On the other hand, a cross-talk between alpha7-nAChR and the Wnt/beta-catenin signaling pathway was revealed by the following facts: (1) nicotine stabilizes beta-catenin, in a concentration-dependent manner; (2) nicotine prevents Abeta-induced loss of beta-catenin through the alpha7-nAChR; and (3) activation of canonical Wnt/beta-catenin signaling induces alpha7-nAChR expression. Nicotine 137-145 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 277-289 23842742-5 2013 On the other hand, a cross-talk between alpha7-nAChR and the Wnt/beta-catenin signaling pathway was revealed by the following facts: (1) nicotine stabilizes beta-catenin, in a concentration-dependent manner; (2) nicotine prevents Abeta-induced loss of beta-catenin through the alpha7-nAChR; and (3) activation of canonical Wnt/beta-catenin signaling induces alpha7-nAChR expression. Nicotine 212-220 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 40-52 23958943-12 2013 These data suggest that disruption of alpha5* nAChR signaling greatly expands the range of nicotine doses that facilitate brain reward activity, which may help explain the increased tobacco addiction vulnerability associated with CHRNA5 risk alleles. Nicotine 91-99 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 46-51 23995055-4 2013 The nicotine-induced (1.0 mg/kg, s.c.) improvement was significantly abolished by the nAChR antagonist mecamylamine (1.0 mg/kg, i.p.). Nicotine 4-12 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 86-91 23995055-10 2013 These findings revealed that nicotine improved spontaneous alternation behavior of GM3(-/-) mice via the activation of alpha4beta2, but not alpha7, nAChR. Nicotine 29-37 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 148-153 23583933-7 2013 In nicotine treated wild-type mice, both alpha4beta2* and alpha7 nAChR binding sites were increased compared with saline treated controls. Nicotine 3-11 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 58-70 23583933-10 2013 Our data highlight the involvement of adenosine A(2A)Rs in the mechanisms of nicotine-induced alpha7 nAChR upregulation, and identify A(2A)Rs as novel pharmacological targets for modulating the long-term effects of nicotine on alpha7 receptors. Nicotine 77-85 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 101-106 23416040-2 2013 The limited available animal studies implicate a role for the alpha5 and beta4 nAChR subunits in nicotine dependence and withdrawal; however studies focusing on the behavioral role of the alpha3beta4* nAChR receptor subtype in nicotine dependence are lacking. Nicotine 97-105 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 79-84 23579386-6 2013 Interestingly, at the subthresold doses, flunarizine, nicardipine, amlodipine, verapamil, and bupropion, a nAChR antagonist, significantly reversed the nicotine improvement of memory acquisition, while flunarizine, verapamil, and bupropion attenuated the improvement of memory consolidation provoked by an acute injection of nicotine (0.035 mg/kg, s.c.). Nicotine 152-160 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 107-112 23416040-3 2013 Because of the apparent role of the alpha3beta4* nAChR subtype in nicotine dependence, the goal of the current study was to better evaluate the involvement of this subtype in nicotine mediated behavioral responses. Nicotine 66-74 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 49-54 23416040-10 2013 Our findings suggest an important role for the alpha3beta4* nAChR subtype in nicotine reward and physical aspects of the nicotine withdrawal syndrome. Nicotine 77-85 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 60-65 23416040-10 2013 Our findings suggest an important role for the alpha3beta4* nAChR subtype in nicotine reward and physical aspects of the nicotine withdrawal syndrome. Nicotine 121-129 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 60-65 23524566-6 2013 The nicotine-induced theta activity was also inhibited selectively by non-alpha7*nAChR antagonists, suggesting the presence of these receptor types on GABAergic and glutamatergic neuron populations in the MSDB. Nicotine 4-12 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 74-80 23524566-6 2013 The nicotine-induced theta activity was also inhibited selectively by non-alpha7*nAChR antagonists, suggesting the presence of these receptor types on GABAergic and glutamatergic neuron populations in the MSDB. Nicotine 4-12 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 81-86 23431157-0 2013 Contribution of alpha7 nicotinic receptor to airway epithelium dysfunction under nicotine exposure. Nicotine 81-89 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 16-41 22614008-0 2013 Nicotine/cigarette smoke promotes metastasis of pancreatic cancer through alpha7nAChR-mediated MUC4 upregulation. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 74-85 22614008-4 2013 This nicotine-mediated MUC4 overexpression was via the alpha7 subunit of nicotinic acetylcholine receptor (nAChR) stimulation and subsequent activation of the JAK2/STAT3 downstream signaling cascade in cooperation with the MEK/ERK1/2 pathway; this effect was blocked by the alpha7nAChR antagonists, alpha-bungarotoxin and mecamylamine, and by specific siRNA-mediated STAT3 inhibition. Nicotine 5-13 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 107-112 22614008-4 2013 This nicotine-mediated MUC4 overexpression was via the alpha7 subunit of nicotinic acetylcholine receptor (nAChR) stimulation and subsequent activation of the JAK2/STAT3 downstream signaling cascade in cooperation with the MEK/ERK1/2 pathway; this effect was blocked by the alpha7nAChR antagonists, alpha-bungarotoxin and mecamylamine, and by specific siRNA-mediated STAT3 inhibition. Nicotine 5-13 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 274-285 23486955-6 2013 Since nAChR subunits are differentially expressed across layers of the PFC neuronal network, we hypothesized that cholinergic signaling through nAChRs across layers would suffer differentially from exposure to nicotine. Nicotine 210-218 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 6-11 23724059-4 2013 Consistently, nicotine elicits seizures through nAChRs and mimics the excessive nAChR activation observed in animal models of the disease. Nicotine 14-22 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 48-53 23637165-0 2013 Targeted deletion of the mouse alpha2 nicotinic acetylcholine receptor subunit gene (Chrna2) potentiates nicotine-modulated behaviors. Nicotine 105-113 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 38-70 23637165-7 2013 Overall, our results suggest that loss of the mouse nAChR alpha2 subunit has very limited effects on baseline behavior but does lead to the potentiation of several nicotine-modulated behaviors. Nicotine 164-172 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 52-57 23419392-2 2013 The beta2* nAChR subtype serves as a potential interface for these interactions since they are the principle mediators of nicotine dependence and have recently been shown to modulate some acute responses to ethanol. Nicotine 122-130 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 11-16 23431157-5 2013 Moreover, prolonged nicotine exposure mimics the absence of alpha7 nAChR in mice or its inactivation in vitro in human airway epithelial cell cultures. Nicotine 20-28 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 60-72 23469004-4 2013 Nicotine exposure impairs the ability of NK cells to kill target cells and release cytokines, a process that is largely abrogated by nAChR beta2 deficiency. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 133-138 23219611-9 2013 However, mice treated with the nAChR agonist nicotine and anabasine required a slightly longer time to recover some aspects of normal muscle function in comparison to mice treated with the nAChR antagonist MLA or deltaline. Nicotine 45-53 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 31-36 23028093-4 2013 However, when poly(I:C)-stimulated macrophages were challenged with nicotine plus alpha-bungarotoxin (alpha-BTX), secretion of IL-6 and TNF-alpha was found to be in a level seen with poly(I:C) stimulation only, indicating that alpha7-nAChR, a highly Ca(2+) permeable ion channel sensitive to blockade by alpha-BTX, is involved in this process. Nicotine 68-76 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 227-239 23469004-6 2013 This nAChR subtype also plays a large role in the NK cell-mediated control of melanoma lung metastasis, in a murine lung metastasis model exposed to nicotine. Nicotine 149-157 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 5-10 23469004-7 2013 Our findings suggest nAChR beta2 as a prominent pathway for nicotine induced impairment of NK cell functions which contributes to the occurrence of smoking-related pathologies. Nicotine 60-68 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 21-26 22771693-9 2012 SIGNIFICANCE: This study indicates that nicotine binding to nAChR in mouse tracheal epithelium activates transepithelial ion transport involving adenylyl cyclase activity. Nicotine 40-48 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 60-65 23233221-0 2012 L-theanine inhibits nicotine-induced dependence via regulation of the nicotine acetylcholine receptor-dopamine reward pathway. Nicotine 20-28 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 70-101 23233221-4 2012 L-theanine treatment also reduced the upregulation of the alpha(4), beta(2) and alpha(7) nicotine acetylcholine receptor (nAChR) subunits induced by nicotine in mouse brain regions that related to the dopamine reward pathway, thus decreasing the number of cells that could react to nicotine. Nicotine 89-97 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 122-127 23233221-4 2012 L-theanine treatment also reduced the upregulation of the alpha(4), beta(2) and alpha(7) nicotine acetylcholine receptor (nAChR) subunits induced by nicotine in mouse brain regions that related to the dopamine reward pathway, thus decreasing the number of cells that could react to nicotine. Nicotine 149-157 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 122-127 23233221-7 2012 Overall, the present study showed that L-theanine reduced the nicotine-induced reward effects via inhibition of the nAChR-dopamine reward pathway. Nicotine 62-70 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 116-121 22722030-9 2012 The antinociceptive effect of nicotine was completely abrogated by cotreatment with the selective alpha7 nAchR antagonist methyllycaconitine (MLA) (1.0 mg/kg). Nicotine 30-38 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 98-110 22458409-4 2012 Here, we tested in fetal NSCs the extent to which EtOH and nicotine coregulated known EtOH-sensitive (miR-9, miR-21, miR-153, and miR-335), a nicotine-sensitive miRNA (miR-140-3p), and mRNAs for nicotinic acetylcholine receptor (nAChR) subunits. Nicotine 59-67 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 195-227 22458409-4 2012 Here, we tested in fetal NSCs the extent to which EtOH and nicotine coregulated known EtOH-sensitive (miR-9, miR-21, miR-153, and miR-335), a nicotine-sensitive miRNA (miR-140-3p), and mRNAs for nicotinic acetylcholine receptor (nAChR) subunits. Nicotine 59-67 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 229-234 22458409-10 2012 Finally, EtOH decreased the expression of nAChR subunit mRNAs and, like mecamylamine, prevented the nicotine-associated increase in alpha4 and beta2 nAChR transcripts. Nicotine 100-108 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 149-154 22458409-11 2012 CONCLUSIONS: EtOH and nicotine exert mutually antagonistic, nAChR-mediated effects on teratogen-sensitive miRNAs in fetal NSCs. Nicotine 22-30 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 60-65 23128482-3 2012 Understanding the various nAChR subtypes that exist in brain areas relevant to nicotine addiction is a major priority. Nicotine 79-87 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 26-31 23113262-1 2012 Stimulation of nicotinic and muscarinic cholinoreceptors (nAChR, mAChR) in outbred albino mice with nicotine and aceclidine, respectively, in single equilethal doses 0.5 DL(50)6 h before sepsis induction significantly reduced animal mortality due to a decrease in blood concentrations of proinflammatory cytokines IL-1beta, IL-6, and MIP-2. Nicotine 100-108 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 15-56 23113262-1 2012 Stimulation of nicotinic and muscarinic cholinoreceptors (nAChR, mAChR) in outbred albino mice with nicotine and aceclidine, respectively, in single equilethal doses 0.5 DL(50)6 h before sepsis induction significantly reduced animal mortality due to a decrease in blood concentrations of proinflammatory cytokines IL-1beta, IL-6, and MIP-2. Nicotine 100-108 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 58-63 22546501-8 2012 Nicotine up-regulated the expression of alpha7 nAChR by activating PI3K-Akt pathway in murine DCs; secondly, nicotine stimulation could enhance DCs" ability of HBV-specific T cell proliferation and IL-12 secretion; thirdly, adoptive transfer of nicotine stimulated DCs could induce HBV specific CTL priming in vivo and those CTL had cytolytic activities; fourthly, nicotine had equal efficiencies to 2 ng/ml IFN-gamma in DCs-mediated T cell proliferation. Nicotine 109-117 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 40-52 22579614-9 2012 To conclude, the similar declines in L-dopa-induced AIMs in nicotine-treated wildtype mice and in alpha6-/- mice treated with and without nicotine indicate an essential role for alpha6beta2* nAChRs in the maintenance of L-dopa-induced AIMs.These findings suggest that alpha6beta2* nAChR drugs have potential for reducing L-dopa-induced dyskinesias in Parkinson"s disease. Nicotine 60-68 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 191-196 22579614-9 2012 To conclude, the similar declines in L-dopa-induced AIMs in nicotine-treated wildtype mice and in alpha6-/- mice treated with and without nicotine indicate an essential role for alpha6beta2* nAChRs in the maintenance of L-dopa-induced AIMs.These findings suggest that alpha6beta2* nAChR drugs have potential for reducing L-dopa-induced dyskinesias in Parkinson"s disease. Nicotine 138-146 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 191-196 22546501-2 2012 The present study is to explore HBV-specific CTL priming and its cytolytic activities of nicotine-treated murine DCs, the mechanism of alpha7 nicotinic acetylcholine receptor (nAChR) up-regulation by nicotine and the efficiency of nicotine with other cytokines. Nicotine 200-208 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 176-181 22546501-2 2012 The present study is to explore HBV-specific CTL priming and its cytolytic activities of nicotine-treated murine DCs, the mechanism of alpha7 nicotinic acetylcholine receptor (nAChR) up-regulation by nicotine and the efficiency of nicotine with other cytokines. Nicotine 200-208 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 176-181 22546501-6 2012 The mechanism of nicotine up-regulating alpha7 nAChR was finally explored by Western blot. Nicotine 17-25 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 40-52 22546501-8 2012 Nicotine up-regulated the expression of alpha7 nAChR by activating PI3K-Akt pathway in murine DCs; secondly, nicotine stimulation could enhance DCs" ability of HBV-specific T cell proliferation and IL-12 secretion; thirdly, adoptive transfer of nicotine stimulated DCs could induce HBV specific CTL priming in vivo and those CTL had cytolytic activities; fourthly, nicotine had equal efficiencies to 2 ng/ml IFN-gamma in DCs-mediated T cell proliferation. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 40-52 22546501-8 2012 Nicotine up-regulated the expression of alpha7 nAChR by activating PI3K-Akt pathway in murine DCs; secondly, nicotine stimulation could enhance DCs" ability of HBV-specific T cell proliferation and IL-12 secretion; thirdly, adoptive transfer of nicotine stimulated DCs could induce HBV specific CTL priming in vivo and those CTL had cytolytic activities; fourthly, nicotine had equal efficiencies to 2 ng/ml IFN-gamma in DCs-mediated T cell proliferation. Nicotine 245-253 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 40-52 22546501-8 2012 Nicotine up-regulated the expression of alpha7 nAChR by activating PI3K-Akt pathway in murine DCs; secondly, nicotine stimulation could enhance DCs" ability of HBV-specific T cell proliferation and IL-12 secretion; thirdly, adoptive transfer of nicotine stimulated DCs could induce HBV specific CTL priming in vivo and those CTL had cytolytic activities; fourthly, nicotine had equal efficiencies to 2 ng/ml IFN-gamma in DCs-mediated T cell proliferation. Nicotine 245-253 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 40-52 22532626-5 2012 An increase in alpha4beta2*-nAChR binding sites was observed in hippocampus, but not in diencephalon, after 24 h of treatment with 1 muM nicotine. Nicotine 137-145 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 28-33 22532626-10 2012 Given the differences observed between hippocampus and diencephalon neurons exposed to nicotine, multiple mechanisms may play a role in the regulation of nAChR expression and function. Nicotine 87-95 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 154-159 22562289-7 2012 However, AMs from mice deficient in the alpha7 nicotinic acetylcholine receptor (alpha7 nAChR) had less TGFbeta1, reduced alternative activation, and improved phagocytic functioning despite similar in utero nicotine exposure. Nicotine 207-215 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 40-79 22562289-8 2012 CONCLUSION: In utero nicotine exposure, mediated in part via the alpha7 nAChR, may increase the risk of lower respiratory tract infections in neonates by changing the resting state of AM toward alternative activation. Nicotine 21-29 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 65-77 22241831-10 2012 Using a dose of nicotine selective for beta2*-nAChR subtype effects with these tests, dose-dependent antagonism by varenicline was seen. Nicotine 16-24 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 46-51 22741175-2 2012 The present study examined the efficacy of nAChR ligands with different pharmacological profiles such as cytisine, lobeline and dihydro-beta-erythroidine (DHbetaE) to modulate chronic nicotine-induced increase in ethanol intake by C57BL/6J mice, using a two-bottle choice procedure. Nicotine 184-192 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 43-48 22624500-3 2012 The objective of the present study was to determine whether nicotine-induced neuroprotection in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model occurs via alpha7-nAChR-mediated inhibition of astrocytes. Nicotine 60-68 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 175-187 22624500-7 2012 The protective effects of nicotine were abolished by administration of the alpha7-nAChR-selective antagonist methyllycaconitine (MLA). Nicotine 26-34 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 75-87 22624500-9 2012 CONCLUSION: Taken together, our results suggest that alpha7-nAChR-mediated inhibition of astrocyte activation is an important mechanism underlying the protective effects of nicotine. Nicotine 173-181 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 53-65 22009521-3 2012 At 3-6 h of spontaneous nicotine/saline withdrawal, thresholds were elevated in nicotine-withdrawing alpha7(+/+) and beta4(+/+), but not alpha7(-/-) or beta4(-/-), mice compared with saline-withdrawing mice, indicating a delay in the onset of withdrawal in the knockout mice. Nicotine 24-32 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 101-107 22009521-0 2012 Role of alpha7- and beta4-containing nicotinic acetylcholine receptors in the affective and somatic aspects of nicotine withdrawal: studies in knockout mice. Nicotine 111-119 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 8-14 22009521-3 2012 At 3-6 h of spontaneous nicotine/saline withdrawal, thresholds were elevated in nicotine-withdrawing alpha7(+/+) and beta4(+/+), but not alpha7(-/-) or beta4(-/-), mice compared with saline-withdrawing mice, indicating a delay in the onset of withdrawal in the knockout mice. Nicotine 80-88 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 101-107 22009521-8 2012 In conclusion, null mutation of the alpha7 and beta4 nAChR subunits resulted in a delayed onset of the anhedonic aspects of the spontaneous nicotine withdrawal syndrome. Nicotine 140-148 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 36-42 22009521-8 2012 In conclusion, null mutation of the alpha7 and beta4 nAChR subunits resulted in a delayed onset of the anhedonic aspects of the spontaneous nicotine withdrawal syndrome. Nicotine 140-148 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 53-58 22009521-11 2012 In summary, the present results indicate an important role for alpha7 and beta4-containing nAChRs in the anhedonic or somatic signs of nicotine withdrawal. Nicotine 135-143 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 63-69 22239849-0 2012 Low concentrations of nicotine differentially desensitize nicotinic acetylcholine receptors that include alpha5 or alpha6 subunits and that mediate synaptosomal neurotransmitter release. Nicotine 22-30 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 58-91 22521799-4 2012 Developmental differences in nAChR binding were associated with the effects of nicotine withdrawal on contextual learning. Nicotine 79-87 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 29-34 22285742-3 2012 Chronic nicotine treatment upregulates nicotinic acetylcholine receptors (nAChR); however, it is unknown whether upregulation is related to the observed withdrawal-induced cognitive deficits. Nicotine 8-16 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 39-72 22285742-3 2012 Chronic nicotine treatment upregulates nicotinic acetylcholine receptors (nAChR); however, it is unknown whether upregulation is related to the observed withdrawal-induced cognitive deficits. Nicotine 8-16 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 74-79 22285742-4 2012 If a relationship between altered learning and nAChR levels exists, changes in nAChR levels after cessation of nicotine treatment should match the duration of learning deficits. Nicotine 111-119 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 47-52 22285742-4 2012 If a relationship between altered learning and nAChR levels exists, changes in nAChR levels after cessation of nicotine treatment should match the duration of learning deficits. Nicotine 111-119 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 79-84 22285742-6 2012 Changes in [(125)I]-epibatidine binding at cytisine-sensitive and cytisine-resistant nAChRs and chronic nicotine-related changes in alpha4, alpha7, and beta2 nAChR subunit mRNA expression were assessed. Nicotine 104-112 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 132-157 22285742-9 2012 Chronic nicotine upregulated hippocampal cytisine-sensitive nAChR binding; upregulation continued after cessation of nicotine administration and the duration of upregulation during withdrawal paralleled the duration of behavioral changes. Nicotine 8-16 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 60-65 22285742-12 2012 Thus, nicotine withdrawal-related deficits in contextual learning are time-limited changes that are associated with temporal changes in upregulation of high-affinity nAChR binding. Nicotine 6-14 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 166-171 22239849-2 2012 Several subtypes of nAChR have high sensitivity to nicotine and mediate effects of nicotine at concentrations found in blood of tobacco smokers. Nicotine 51-59 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 20-25 22239849-2 2012 Several subtypes of nAChR have high sensitivity to nicotine and mediate effects of nicotine at concentrations found in blood of tobacco smokers. Nicotine 83-91 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 20-25 22138237-7 2012 The effect of nicotine on weight loss in mice on an HFD was completely blocked by mecamylamine, a nonselective nicotinic acetylcholine receptor (nAChR) antagonist, but only partially blocked by the alpha4beta2 nAChR partial agonist/antagonist, varenicline. Nicotine 14-22 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 111-143 22138237-7 2012 The effect of nicotine on weight loss in mice on an HFD was completely blocked by mecamylamine, a nonselective nicotinic acetylcholine receptor (nAChR) antagonist, but only partially blocked by the alpha4beta2 nAChR partial agonist/antagonist, varenicline. Nicotine 14-22 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 145-150 22138237-7 2012 The effect of nicotine on weight loss in mice on an HFD was completely blocked by mecamylamine, a nonselective nicotinic acetylcholine receptor (nAChR) antagonist, but only partially blocked by the alpha4beta2 nAChR partial agonist/antagonist, varenicline. Nicotine 14-22 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 210-215 22108649-3 2012 Monoamine release is facilitated by nAChR stimulation, and nicotine-evoked serotonin (5-HT) release has been shown to depend on alpha7 nAChR activation. Nicotine 59-67 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 135-140 22396410-1 2012 Polymorphisms in the gene for the alpha5 nicotinic acetylcholine receptor (nAChR) subunit are associated with vulnerability to nicotine addiction. Nicotine 127-135 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 75-80 22349092-15 2012 In this paper we describe a methodology to quantify changes in nAChR expression in specific CNS neurons after exposure to chronic nicotine. Nicotine 130-138 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 63-68 23251458-9 2012 All together, these findings demonstrated that nicotine enhanced insulin sensitivity in animals with or without insulin resistance, at least in part via stimulating alpha7-nAChR-STAT3 pathway independent of inflammation. Nicotine 47-55 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 165-177 23056257-7 2012 Both effects of nicotine were significantly prevented by the heteromeric alpha4beta2 nAChR subtype antagonists dihydro-beta-erythroidine and 4-(5-ethoxy-3-pyridinyl)-N-methyl-(3E)-3-buten-1-amine, but not by the homomeric alpha7 nAChR subtype antagonist methyllycaconitine, in murine progenitors. Nicotine 16-24 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 222-234 22036617-9 2011 Moreover, nicotine-induced analgesia was suppressed by dihydro-beta-erythroidine (DHbetaE; an antagonist for the alpha4beta2 nAChR) or methyllycaconitine (MLA; an antagonist for the alpha7 nAChR). Nicotine 10-18 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 125-130 22036617-9 2011 Moreover, nicotine-induced analgesia was suppressed by dihydro-beta-erythroidine (DHbetaE; an antagonist for the alpha4beta2 nAChR) or methyllycaconitine (MLA; an antagonist for the alpha7 nAChR). Nicotine 10-18 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 182-194 21740894-8 2011 Most recently, alpha5-containing nAChRs located in the habenulo-interpeduncular tract were shown to limit intravenous nicotine self-administration behavior in rats and mice, suggesting that deficits in alpha5-containing nAChR signaling in the habenulo-interpeduncular tract increases vulnerability to the motivational properties of nicotine. Nicotine 118-126 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 33-38 21740894-8 2011 Most recently, alpha5-containing nAChRs located in the habenulo-interpeduncular tract were shown to limit intravenous nicotine self-administration behavior in rats and mice, suggesting that deficits in alpha5-containing nAChR signaling in the habenulo-interpeduncular tract increases vulnerability to the motivational properties of nicotine. Nicotine 332-340 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 33-38 21740894-10 2011 The aim of the present review is to discuss recent preclinical findings concerning the identity of the nAChR subtypes that regulate self-administration of nicotine and other drugs of abuse. Nicotine 155-163 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 103-108 21768117-11 2011 In contrast, chronic nicotine substantially increased the number of alpha4beta2-containing vesicle fusions at the PM; this stage in alpha4beta2 nAChR up-regulation is presumably downstream from increased ER exit. Nicotine 21-29 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 144-149 21828053-7 2011 In contrast, mutations of Tyr-195 in alpha7-nAChR led to decreased activation by nicotine without apparent effects on ACh- or Abeta-induced responses. Nicotine 81-89 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 37-49 21083424-1 2011 Activation of nicotinic acetylcholine receptor alpha7 subunit (alpha7nAChR) by nicotine leads to the improved survival rate in experimental model of sepsis. Nicotine 79-87 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 63-74 21784975-0 2011 Cytokine-induced alterations of alpha7 nicotinic receptor in colonic CD4 T cells mediate dichotomous response to nicotine in murine models of Th1/Th17- versus Th2-mediated colitis. Nicotine 113-121 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 32-57 21665941-4 2011 An important question is the nicotinic acetylcholine receptor (nAChR) subtypes through which nicotine exerts this beneficial effect, because such knowledge would allow for the development of drugs that target the relevant receptor population(s). Nicotine 93-101 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 29-61 21665941-4 2011 An important question is the nicotinic acetylcholine receptor (nAChR) subtypes through which nicotine exerts this beneficial effect, because such knowledge would allow for the development of drugs that target the relevant receptor population(s). Nicotine 93-101 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 63-68 21640128-5 2011 The nicotinic acetylcholine receptor (nAChR) antagonist mecamylamine decreased responding for nicotine, but not food rewards, verifying that nAChRs regulate nicotine self-administration in mice. Nicotine 94-102 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 4-36 21640128-5 2011 The nicotinic acetylcholine receptor (nAChR) antagonist mecamylamine decreased responding for nicotine, but not food rewards, verifying that nAChRs regulate nicotine self-administration in mice. Nicotine 94-102 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 38-43 21640128-5 2011 The nicotinic acetylcholine receptor (nAChR) antagonist mecamylamine decreased responding for nicotine, but not food rewards, verifying that nAChRs regulate nicotine self-administration in mice. Nicotine 157-165 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 4-36 21640128-5 2011 The nicotinic acetylcholine receptor (nAChR) antagonist mecamylamine decreased responding for nicotine, but not food rewards, verifying that nAChRs regulate nicotine self-administration in mice. Nicotine 157-165 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 38-43 22276424-4 2011 Pre-incubation of the isolated mitochondria with nicotine prevented from dissipation of their membrane potential stimulated with 0.8 microM CaCl2 depending on the dose, and this effect was strengthened by the antagonist of alpha7 nicotinic receptors (alpha7 nAChR) methyllicaconitine. Nicotine 49-57 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 223-263 22276424-7 2011 It is concluded that nicotine consumption worsens the functional state of mitochondria by affecting their membrane potential and granularity, and this effect, at least in part, is mediated by alpha7 nAChR desensitization. Nicotine 21-29 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 192-204 21083424-7 2011 Collectively, these data suggest that activation of alpha7nAChR by nicotine is critical in the regulation of anti-inflammatory process, which could be mediated through HO-1 expression. Nicotine 67-75 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 52-63 21083424-8 2011 Thus, we conclude that activation of alpha7nAChR by nicotine provides anti-inflammatory action through HO-1 upregulation. Nicotine 52-60 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 37-48 21083424-3 2011 However, that activation of alpha7nAChR by nicotine provides anti-inflammatory action through HO-1 upregulation has not been elucidated. Nicotine 43-51 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 28-39 21486776-6 2011 Expression of the A2A receptor in HEK cells also increased the apparent potency of nAChR for nicotine, further supporting a general A2A-induced gain of function for nAChR. Nicotine 93-101 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 83-88 21486776-6 2011 Expression of the A2A receptor in HEK cells also increased the apparent potency of nAChR for nicotine, further supporting a general A2A-induced gain of function for nAChR. Nicotine 93-101 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 165-170 20974182-0 2011 Role of mouse cerebellar nicotinic acetylcholine receptor (nAChR) alpha(4)beta(2)- and alpha(7) subtypes in the behavioral cross-tolerance between nicotine and ethanol-induced ataxia. Nicotine 147-155 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 25-57 21555077-1 2011 Nicotine dependence is linked to single nucleotide polymorphisms in the CHRNB4-CHRNA3-CHRNA5 gene cluster encoding the alpha3beta4alpha5 nicotinic acetylcholine receptor (nAChR). Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 171-176 21228066-2 2011 Nicotine-induced up-regulation of alpha4beta2-nicotinic acetylcholine receptors (nAChRs) in cell cultures results from increased assembly and/or decreased degradation of nAChRs, leading to increased nAChR protein levels. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 81-86 21228066-11 2011 Thus, increases in alpha4beta2*-nAChR binding sites after chronic nicotine treatment reflect increased nAChR protein. Nicotine 66-74 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 32-37 21228066-11 2011 Thus, increases in alpha4beta2*-nAChR binding sites after chronic nicotine treatment reflect increased nAChR protein. Nicotine 66-74 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 103-108 21239887-6 2011 Consistent with this result, here we show that a more efficacious nAChR agonist, nicotine, also decreased voluntary ethanol intake, and that alpha4* nAChRs are critical for this reduction. Nicotine 81-89 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 66-71 21167848-6 2011 The high-affinity nAChR antagonist Dihydro-beta-erythroidine hydrobromide (DhbetaE) blocked the effects of nicotine on MK-801-induced deficits while the alpha7 nAChR antagonist methyllycaconitine citrate salt hydrate (MLA) did not. Nicotine 107-115 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 18-23 21143250-0 2011 The role of nicotinic acetylcholine receptor (nAChR) alpha7 subtype in the functional interaction between nicotine and ethanol in mouse cerebellum. Nicotine 106-114 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 12-44 21143250-0 2011 The role of nicotinic acetylcholine receptor (nAChR) alpha7 subtype in the functional interaction between nicotine and ethanol in mouse cerebellum. Nicotine 106-114 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 46-51 21143250-4 2011 The intracerebellar (ICB) administration of nicotine significantly attenuates ethanol ataxia through nicotinic acetylcholine receptor (nAChR) alpha(4)beta(2) subtype. Nicotine 44-52 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 101-133 21143250-4 2011 The intracerebellar (ICB) administration of nicotine significantly attenuates ethanol ataxia through nicotinic acetylcholine receptor (nAChR) alpha(4)beta(2) subtype. Nicotine 44-52 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 135-140 21143250-14 2011 Overall, the results demonstrate the role of cerebellar nAChR alpha(7) subtype in nicotine-induced attenuation of ethanol-induced ataxia in cerebellar NO(x)-sensitive manner. Nicotine 82-90 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 56-61 21239433-8 2011 These data suggest that alpha7nAChR is important in mediating the antiinflammatory effect of nicotine. Nicotine 93-101 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 24-35 20974182-0 2011 Role of mouse cerebellar nicotinic acetylcholine receptor (nAChR) alpha(4)beta(2)- and alpha(7) subtypes in the behavioral cross-tolerance between nicotine and ethanol-induced ataxia. Nicotine 147-155 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 59-64 20974182-1 2011 We have demonstrated that nicotine attenuated ethanol-induced ataxia via nicotinic-acetylcholine-receptor (nAChR) subtypes alpha(4)beta(2) and alpha(7). Nicotine 26-34 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 107-112 20974182-15 2011 Our results support a role for alpha(4)beta(2) and alpha(7) nAChR subtypes in the development of cross-tolerance between nicotine and ethanol with the NO signaling pathway as a potential mechanism. Nicotine 121-129 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 51-65 21691039-1 2011 We have reported that nicotine and the specific alpha7AChR agonist ameliorate indomethacin-induced intestinal lesions in mice by activating alpha7 nicotinic acetylcholine receptors (alpha7nAChR). Nicotine 22-30 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 140-180 20932827-3 2011 Here we show that nicotine exposure attenuates EAE severity and that this effect is largely abolished in nAChR alpha7 subunit knock-out mice. Nicotine 18-26 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 105-110 20932827-5 2011 Diverse effects of nicotine on effector and regulatory T cells, as well as antigen-presenting cells, may be linked to differential expression patterns of nAChR subunits across these cell types. Nicotine 19-27 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 154-159 20932827-6 2011 Taken together, our data show that although alpha7-nAChRs indeed seem to play an important role in nicotine-conferred reduction of the CNS inflammatory response and protection against EAE, other nAChR subtypes also are involved in the anti-inflammatory properties of the cholinergic system. Nicotine 99-107 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 51-56 21691039-1 2011 We have reported that nicotine and the specific alpha7AChR agonist ameliorate indomethacin-induced intestinal lesions in mice by activating alpha7 nicotinic acetylcholine receptors (alpha7nAChR). Nicotine 22-30 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 182-193 21966399-10 2011 Furthermore, alpha7 nAChR is the major calcium channel for nicotine- and E. coli K1-increased intracellular calcium concentrations of mouse BMEC. Nicotine 59-67 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 20-25 20843956-0 2010 Stimulation of alpha7 nicotinic acetylcholine receptor by nicotine increases suppressive capacity of naturally occurring CD4+CD25+ regulatory T cells in mice in vitro. Nicotine 58-66 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 15-54 20843956-4 2010 We found that CD4(+)CD25(+) Tregs from naive C57BL/6J mice positively expressed alpha7 nAChR, and its activation by nicotine enhanced the suppressive capacity of Tregs. Nicotine 116-124 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 80-92 20843956-7 2010 The above-mentioned effects of nicotine were reversed by a selective alpha7 nAChR antagonist, alpha-bungarotoxin. Nicotine 31-39 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 69-81 20843956-9 2010 We conclude that nicotine might increase Treg-mediated immune suppression of lymphocytes via alpha7 nAChR. Nicotine 17-25 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 93-105 20595621-4 2010 Nicotine"s effect on hyperexcitability of inflamed neurons was blocked in the presence of an alpha(7)-nicotinic acetylcholine receptor (nAChR) antagonist, methyllicaconitine, while choline, the alpha(7)-nAChR agonist, induced a similar effect to that of nicotine. Nicotine 254-262 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 136-141 20561218-7 2010 RESULTS: Murine periodontal ligament cells expressed several subunits of nAChR, which have functional calcium signals in response to nicotine. Nicotine 133-141 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 73-78 20599770-4 2010 The studies described here evaluated desensitization elicited by low concentrations of epibatidine, nicotine, cytisine or methylcarbachol of brain alpha4beta2-nAChR function measured with acetylcholine-stimulated (86)Rb(+) efflux from mouse thalamic synaptosomes. Nicotine 100-108 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 159-164 20731631-1 2010 Neuronal nAChR upregulation is the hallmark of chronic nicotine exposure. Nicotine 55-63 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 9-14 20736992-9 2010 Taken together, these studies identify a novel consequence of developmental nicotine exposure in the mouse, define the nAChR subtypes and neural circuit involved in this behavioral change and delimit the neurodevelopmental period critical for vulnerability to a behavioral alteration that persists into adulthood. Nicotine 76-84 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 119-124 20595621-4 2010 Nicotine"s effect on hyperexcitability of inflamed neurons was blocked in the presence of an alpha(7)-nicotinic acetylcholine receptor (nAChR) antagonist, methyllicaconitine, while choline, the alpha(7)-nAChR agonist, induced a similar effect to that of nicotine. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 93-134 20595621-4 2010 Nicotine"s effect on hyperexcitability of inflamed neurons was blocked in the presence of an alpha(7)-nicotinic acetylcholine receptor (nAChR) antagonist, methyllicaconitine, while choline, the alpha(7)-nAChR agonist, induced a similar effect to that of nicotine. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 136-141 20595621-4 2010 Nicotine"s effect on hyperexcitability of inflamed neurons was blocked in the presence of an alpha(7)-nicotinic acetylcholine receptor (nAChR) antagonist, methyllicaconitine, while choline, the alpha(7)-nAChR agonist, induced a similar effect to that of nicotine. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 194-208 20496163-2 2010 A site of action for both nicotine and alcohol effects in the brain are neuronal nicotinic acetylcholine receptors (nAChR). Nicotine 26-34 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 81-114 20496163-2 2010 A site of action for both nicotine and alcohol effects in the brain are neuronal nicotinic acetylcholine receptors (nAChR). Nicotine 26-34 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 116-121 19812239-7 2010 Tonically applied nicotine (1-100 microM) increased the frequency of spontaneous GABAergic inhibitory postsynaptic currents (IPSCs) on pyramidal neurons in PFC layer V. The contribution of nAChR types was assessed by using 1 microM dihydro-beta-erythroidine (DHbetaE), to block heteromeric nAChRs, and 10 nM methyllycaconitine (MLA), to block homomeric nAChRs. Nicotine 18-26 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 189-194 20580908-3 2010 Recently, it is demonstrated that mecamylamine, a nAChR antagonist blocks cocaine-, d-amphetamine-, ephedrine-, nicotine-, and methylphenidate-induced psychomotor sensitization. Nicotine 112-120 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 50-55 20702707-8 2010 The effects of nicotine and epibatidine were independent on nicotinic ACh receptor (nAChR) activation because they persisted in the presence of nAChR antagonists. Nicotine 15-23 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 144-149 19778953-12 2010 In conclusion, the current study shows for the first time that chronic exposure to nicotine impairs cholinergic angiogenesis, an effect mediated by downregulation of the vascular nAChR, and attenuation of nicotine-induced VEGF release. Nicotine 83-91 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 179-184 20400469-3 2010 Thus, additional studies are imperative to elucidate the role and function of the alpha5 nAChR subunit in nicotine dependence. Nicotine 106-114 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 89-94 20400469-6 2010 Results show that alpha5(-/-) mice are less sensitive to the initial effects of nicotine in antinociception, locomotor activity, and hypothermia measures and that the alpha5 nAChR is involved in nicotine reward. Nicotine 80-88 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 174-179 20400469-6 2010 Results show that alpha5(-/-) mice are less sensitive to the initial effects of nicotine in antinociception, locomotor activity, and hypothermia measures and that the alpha5 nAChR is involved in nicotine reward. Nicotine 195-203 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 174-179 20413096-6 2010 These data identify a mechanism for the negative regulation of host-innate AMP response to infection through cholinergic activation and indicate nAChR-mediated cathelicidin dysregulation as a potential mechanism for increased susceptibility to infection following prolonged stress or nicotine use. Nicotine 284-292 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 145-150 20203212-9 2010 Conversely, in mice lacking the alpha7 nAChR, the decay rate, but not the amplitude, of nicotine-evoked cholinergic and glutamatergic transients was attenuated. Nicotine 88-96 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 32-44 20061993-4 2010 However, one genetic variant has been implicated in altering nicotine sensitivity in mice is a T529A polymorphism in Chrna4, the gene that encodes the nicotinic receptor (nAChR) alpha4 subunit. Nicotine 61-69 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 171-176 19940180-5 2009 Misexpressing PSCA before cell death in the ciliary ganglion blocks alpha7-nAChR activation by nicotine and rescues the choroid subpopulation from dying. Nicotine 95-103 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 68-80 19749751-6 2009 In the presence of the general nAChR blocker hexamethonium, nociceptive neurons showed nicotine-induced responses that were strongly reduced in TRPA1-deficient mice. Nicotine 87-95 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 31-36 19812319-7 2009 These data suggest that in nigrostriatal DA pathway, chronic nicotine enhancement of alpha4beta2* nAChRs displays selectivity in cell type and in nAChR subtype as well as in cellular compartment. Nicotine 61-69 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 98-103 19576867-10 2009 Finally, we have shown that early adolescent nicotine exposure significantly elevates nAChR function in adulthood. Nicotine 45-53 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 86-91 19435931-2 2009 Thus, understanding the nicotinic acetylcholine receptor (nAChR) subtypes and subsequent molecular cascades activated after nicotine exposure is of the utmost importance in understanding the progression of nicotine dependence. Nicotine 124-132 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 24-56 19619852-8 2009 Moreover, in this established cell line, PNU-282987, a selective alpha7nAChR agonist, exerted a stronger ability to reduce TNF-alpha release than nicotine. Nicotine 146-154 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 65-76 19435931-2 2009 Thus, understanding the nicotinic acetylcholine receptor (nAChR) subtypes and subsequent molecular cascades activated after nicotine exposure is of the utmost importance in understanding the progression of nicotine dependence. Nicotine 124-132 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 58-63 19435931-2 2009 Thus, understanding the nicotinic acetylcholine receptor (nAChR) subtypes and subsequent molecular cascades activated after nicotine exposure is of the utmost importance in understanding the progression of nicotine dependence. Nicotine 206-214 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 24-56 19435931-2 2009 Thus, understanding the nicotinic acetylcholine receptor (nAChR) subtypes and subsequent molecular cascades activated after nicotine exposure is of the utmost importance in understanding the progression of nicotine dependence. Nicotine 206-214 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 58-63 19435931-8 2009 In contrast, alpha7 nAChR KO mice show nicotine-induced increases in CaMKII activity and pCREB, similar to their wild-type littermates. Nicotine 39-47 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 20-25 19326440-2 2009 Nicotine (classical nAChR agonist) induced cell proliferation, whereas nAChR antagonists, d- tubocurarine or alpha-cobratoxin (alpha-CbT), induced cell death. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 20-25 19452140-11 2009 DISCUSSION: It is suggested that the increased sensitivity to antidepressants after chronic nicotine exposure involves increased high-affinity nAChR-mediated neurotransmission. Nicotine 92-100 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 143-148 19020025-3 2008 Although the beta2 subunit of the neuronal nicotinic acetylcholine receptor (nAChR) has been shown to play a crucial role in mediating the reinforcement properties of nicotine, little is known about the contribution of the different alpha subunit partners of beta2 (i.e., alpha4 and alpha6), the homo-pentameric alpha7, and the brain areas other than the ventral tegmental area (VTA) involved in nicotine reinforcement. Nicotine 167-175 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 77-82 19151195-2 2009 The nAChR alpha7 subunit has been found to be pivotal in the control of nicotine-induced lung cancer development and in growth signal transduction induced by nicotine binding to nAChRs. Nicotine 72-80 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 4-9 19151195-2 2009 The nAChR alpha7 subunit has been found to be pivotal in the control of nicotine-induced lung cancer development and in growth signal transduction induced by nicotine binding to nAChRs. Nicotine 158-166 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 4-9 18758759-9 2009 Further support for an alpha7 nicotinic receptor-mediated component was provided by the ability of the alpha7 nicotinic receptor antagonist methyllycaconitine to attenuate responses to nicotine and amphetamine in wild-type mice. Nicotine 185-193 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 23-48 18758759-9 2009 Further support for an alpha7 nicotinic receptor-mediated component was provided by the ability of the alpha7 nicotinic receptor antagonist methyllycaconitine to attenuate responses to nicotine and amphetamine in wild-type mice. Nicotine 185-193 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 103-128 18758759-10 2009 CONCLUSIONS: These findings support the concept of an alpha7 nicotinic receptor-mediated dopaminergic element in nicotine discrimination, warranting further tests with selective dopamine agonists. Nicotine 113-121 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 54-79 19020025-3 2008 Although the beta2 subunit of the neuronal nicotinic acetylcholine receptor (nAChR) has been shown to play a crucial role in mediating the reinforcement properties of nicotine, little is known about the contribution of the different alpha subunit partners of beta2 (i.e., alpha4 and alpha6), the homo-pentameric alpha7, and the brain areas other than the ventral tegmental area (VTA) involved in nicotine reinforcement. Nicotine 396-404 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 77-82 18582447-2 2008 It has been shown that the non-selective nicotinic agonist nicotine has an influence on auditory gating in part by acting on the alpha4beta2 nAChR. Nicotine 59-67 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 141-146 18571741-7 2008 Similarly, research in mice has provided evidence that naturally occurring variability in nAChR genes is associated with changes in nicotine sensitivity. Nicotine 132-140 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 90-95 18571741-8 2008 Furthermore, the use of genetic knockout mice has allowed researchers to determine the nAChR genes that mediate the effects of nicotine, whereas research with knockin mice has demonstrated that changes to nAChR genes can dramatically alter nicotine sensitivity. Nicotine 127-135 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 87-92 18571741-8 2008 Furthermore, the use of genetic knockout mice has allowed researchers to determine the nAChR genes that mediate the effects of nicotine, whereas research with knockin mice has demonstrated that changes to nAChR genes can dramatically alter nicotine sensitivity. Nicotine 240-248 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 205-210 18812210-3 2008 The present study was designed to determine the possible involvement of specific nicotinic acetylcholine receptor (nAChR) subtype alpha(4)beta(2) in nicotine-induced attenuation of ethanol ataxia. Nicotine 149-157 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 81-113 18812210-3 2008 The present study was designed to determine the possible involvement of specific nicotinic acetylcholine receptor (nAChR) subtype alpha(4)beta(2) in nicotine-induced attenuation of ethanol ataxia. Nicotine 149-157 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 115-120 18812210-11 2008 In conclusion, the results of the present investigation support an important role of alpha(4)beta(2) nAChR subtype in the expression of nicotine-induced attenuation of ethanol ataxia. Nicotine 136-144 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 101-106 18690103-6 2008 Here, we review data generated from nAChR subunit knockout and genetically modified mice supporting a role for discrete nAChR subunits in nicotine reinforcement and dependence processes. Nicotine 138-146 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 36-41 18690103-6 2008 Here, we review data generated from nAChR subunit knockout and genetically modified mice supporting a role for discrete nAChR subunits in nicotine reinforcement and dependence processes. Nicotine 138-146 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 120-125 18583454-8 2008 To elucidate the alpha6beta2(*) nAChR subtypes altered with long-term nicotine treatment, we used the novel alpha-CtxMII analog E11A in combination with alpha4 nAChR knockout mice. Nicotine 70-78 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 32-37 18077004-3 2008 Cytokine responses to UV in mice administered chronic oral nicotine, a nAChR agonist, were reduced. Nicotine 59-67 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 71-76 18452957-3 2008 Nicotine withdrawal was induced by termination of chronic nicotine delivery through osmotic minipumps or precipitated with the nicotinic acetylcholine receptor (nAChR) antagonists mecamylamine or dihydro-beta-erythroidine (DHbetaE). Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 127-159 18452957-3 2008 Nicotine withdrawal was induced by termination of chronic nicotine delivery through osmotic minipumps or precipitated with the nicotinic acetylcholine receptor (nAChR) antagonists mecamylamine or dihydro-beta-erythroidine (DHbetaE). Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 161-166 18184829-6 2008 Our results show a loss of anxiety-related behavior and a loss of aversion in the CPA model in beta2 KO mice, whereas alpha7 and alpha5 KO mice displayed a loss of nicotine withdrawal-induced hyperalgesia and a reduction in somatic signs, respectively. Nicotine 164-172 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 118-124 18184829-7 2008 These results suggest that beta2-containing nAChRs are involved in the affective signs of nicotine withdrawal, whereas non-beta2-containing nAChRs are more closely associated with physical signs of nicotine withdrawal; thus, the nAChR subtype composition may play an important role in the involvement of specific subtypes in nicotine withdrawal. Nicotine 90-98 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 44-49 19492010-5 2008 The nAChRs are important components of the dopaminergic reward system because some of the receptors have been shown to activate the release of dopamine, and mice lacking genes for specific nAChR gene subunits show altered behavioral responses to nicotine and alcohol. Nicotine 246-254 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 4-9 18452957-11 2008 The current study is one of the first to demonstrate reward deficits associated with both spontaneous and nAChR antagonist-precipitated nicotine withdrawal in C57BL/6J mice. Nicotine 136-144 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 106-111 18194436-5 2008 In radioligand binding studies, the specific binding of [3H]-nicotine was not altered in the presence of AEA, indicating that AEA inhibits the function of nAChR in a non-competitive manner. Nicotine 61-69 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 155-160 18385094-3 2008 By stimulating nAChR, nicotine promotes tumor angiogenesis as well as atherosclerotic plaque neovascularization. Nicotine 22-30 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 15-20 18385094-9 2008 CONCLUSIONS: These data suggest that endogenous activation of nAChR promotes CNV and that activation of nAChR by nicotine may contribute to the increased incidence of CNV seen in smokers with age-related macular degeneration (AMD). Nicotine 113-121 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 104-109 17584502-2 2008 However, the nicotinic acetylcholine receptors (nAChR) that are involved in nicotine withdrawal deficits in contextual fear conditioning are unknown. Nicotine 76-84 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 13-46 17584502-2 2008 However, the nicotinic acetylcholine receptors (nAChR) that are involved in nicotine withdrawal deficits in contextual fear conditioning are unknown. Nicotine 76-84 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 48-53 17584502-3 2008 The present study used genetic and pharmacological techniques to investigate the nAChR subtype(s) involved in the effects of nicotine withdrawal on contextual fear conditioning. Nicotine 125-133 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 81-86 17825262-7 2007 One of these three subtypes (alpha4alpha6beta2beta3) also has the highest sensitivity to nicotine of any native nAChR that has been studied, to date. Nicotine 89-97 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 112-117 17920082-2 2007 The alpha7 subunit of the neuronal nicotinic acetylcholine receptor (nAChR) is highly expressed in the brain, and has been suspected to play a major role in nicotine addiction. Nicotine 157-165 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 4-10 17920082-2 2007 The alpha7 subunit of the neuronal nicotinic acetylcholine receptor (nAChR) is highly expressed in the brain, and has been suspected to play a major role in nicotine addiction. Nicotine 157-165 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 35-67 17920082-2 2007 The alpha7 subunit of the neuronal nicotinic acetylcholine receptor (nAChR) is highly expressed in the brain, and has been suspected to play a major role in nicotine addiction. Nicotine 157-165 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 69-74 17920082-7 2007 In alpha7 -/- mice, the somatic effects of MEC-precipitated nicotine withdrawal were significantly reduced. Nicotine 60-68 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 3-9 17920082-12 2007 Our results point to the alpha7 subunit as one of the players in nicotine withdrawal, but not in nicotine tolerance or basal anxiety-like behavior. Nicotine 65-73 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 25-31 17942810-3 2007 Chronic (-)-nicotine, a nAChR agonist, treatment in mice and rats elicits a dose-dependent increase in nAChRs in the brain. Nicotine 12-20 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 24-29 17666046-5 2007 Nicotine-induced ERK phosphorylation was inhibited by high concentrations of mecamylamine, however it was not blocked by other broad nicotinic acetylcholine receptor (nAChR) inhibitors (including hexamethonium and chlorisondamine) or nAChR subtype selective inhibitors (such as methyllycaconitine, alpha-bungarotoxin, dihydro-beta-erythroidine, and alpha-conotoxin Au1B). Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 133-165 17666046-5 2007 Nicotine-induced ERK phosphorylation was inhibited by high concentrations of mecamylamine, however it was not blocked by other broad nicotinic acetylcholine receptor (nAChR) inhibitors (including hexamethonium and chlorisondamine) or nAChR subtype selective inhibitors (such as methyllycaconitine, alpha-bungarotoxin, dihydro-beta-erythroidine, and alpha-conotoxin Au1B). Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 167-172 17666046-5 2007 Nicotine-induced ERK phosphorylation was inhibited by high concentrations of mecamylamine, however it was not blocked by other broad nicotinic acetylcholine receptor (nAChR) inhibitors (including hexamethonium and chlorisondamine) or nAChR subtype selective inhibitors (such as methyllycaconitine, alpha-bungarotoxin, dihydro-beta-erythroidine, and alpha-conotoxin Au1B). Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 234-239 17666046-6 2007 In accord with these pharmacological results, nicotine-induced ERK phosphorylation was normal in primary cultures made from beta2 or alpha7 nAChR subunit knockout mice. Nicotine 46-54 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 133-145 17341654-8 2007 The data indicate that one alpha-CtxMII-sensitive nAChR subtype, prevalent on wild-type dopaminergic terminals, has the lowest EC(50) for a nicotine-mediated function so far measured in mice. Nicotine 140-148 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 50-55 17456735-4 2007 Experimental groups included wild-type mice and both nicotine-induced seizure-sensitive and -resistant nAChR mutant mice. Nicotine 53-61 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 103-108 17431097-4 2007 Then, using an acid-induced acute lung injury mouse model, we found that nicotine, choline, and PNU-282,987 (a specific alpha7 nAChR agonist) decreased excess lung water and lung vascular permeability, and reduced protein concentration in the bronchoalveolar lavage (BAL). Nicotine 73-81 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 120-132 17401441-3 2007 We have now used brain slices to investigate nicotine-induced catecholamine outflow in wild type (WT) and nAChR (beta2 and alpha5) knockout mice for a comparison with rat brain slice preparations. Nicotine 45-53 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 106-111 17371806-9 2007 Our results indicate that alpha(4)beta(2)(*) acetylcholine nicotinic receptors (nAChR) are important in mediating nicotine analgesia in supraspinal responses, while also showing that alpha(4)beta(2)(*)-nAChR and at least one other nAChR subtype appear to modulate spinal actions. Nicotine 114-122 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 80-85 17512560-7 2007 STOP KO mice were hypersensitive to the stimulating locomotor effect of nicotine and, interestingly, their impaired performance in learning the cued version of the water maze were improved by administration of the preferential alpha7 nAChR agonist choline. Nicotine 72-80 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 227-239 17133263-5 2007 The effects of nicotine on the extracellular dopamine release were potentiated by galantamine, but antagonized by mecamylamine, a nAChR antagonist. Nicotine 15-23 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 130-135 17416741-1 2007 We have previously demonstrated that acute intracerebellar nicotine or N-methyl-4-(3-pyridinyl)-3-buten-1-amine (RJR-2403), a selective alpha(4)beta(2) nicotinic acetylcholine receptor (nAChR) agonist, dose dependently attenuates Delta(9)-tetrahydrocannabinol (Delta(9)THC)-induced ataxia. Nicotine 59-67 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 186-191 17610911-4 2007 The enhancing action of nicotine was mediated via alpha7 nAChRs as it was absent in mice null for alpha7 nAChR. Nicotine 24-32 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 50-62 17341654-9 2007 In conclusion, the gene deletion strategy enabled isolation of alpha6* subtypes, and these nAChR subtypes exhibited differential activation by nicotine and cytisine. Nicotine 143-151 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 91-96 17291692-0 2007 Neuroprotection afforded by nicotine against oxygen and glucose deprivation in hippocampal slices is lost in alpha7 nicotinic receptor knockout mice. Nicotine 28-36 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 109-134 17520028-6 2007 Nicotine pretreatment protected mice from renal dysfunction in a dose-dependent manner and through the alpha7nAChR, as attested by the absence of protection in alpha7nAChR-deficient mice. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 103-114 17520028-9 2007 All together, these data highlight that nicotine exerts a protective anti-inflammatory effect during kidney I/R through the cholinergic alpha7nAChR pathway. Nicotine 40-48 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 136-147 17466021-4 2007 Interestingly, these opposing effects of nicotine were absent or greatly reduced in alpha2 nicotinic acetylcholine receptor (nAChR)-knockout (KO) mice, suggesting that an alpha2-containing nAChR subtype mediates these effects. Nicotine 41-49 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 189-194 17466021-6 2007 These effects of nicotine were also absent in alpha2 nAChR-KO mice, suggesting that the enhanced optical signal is related to the nicotine-induced facilitation of LTP induction. Nicotine 130-138 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 53-58 17466021-8 2007 These inhibitory effects of nicotine were absent in alpha2 nAChR-KO mice and, thus, most probably underlie the nicotine-induced suppression of LTP induction. Nicotine 28-36 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 59-64 17466021-8 2007 These inhibitory effects of nicotine were absent in alpha2 nAChR-KO mice and, thus, most probably underlie the nicotine-induced suppression of LTP induction. Nicotine 111-119 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 59-64 17116233-9 2007 The novel integrated use of restricted re-expressed nAChR subunits with in vivo electrophysiology and automated quantitative behavioural analysis enables the further analysis of defined neuronal circuits in nicotine addiction and higher cognitive function. Nicotine 207-215 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 52-57 17275078-1 2007 We have recently reported that mediation of intracerebellar nicotine-induced attenuation of cerebellar delta9-THC ataxia was via the alpha4beta2 nAChR. Nicotine 60-68 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 145-150 17136517-3 2007 Similarly, genetic deletion of the beta2 nAChR subunit but not the alpha7 nAChR subunit blocked the enhancing effect of nicotine on contextual fear conditioning. Nicotine 120-128 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 41-46 17136517-8 2007 RESULTS: Both contextual and trace cued fear conditioning were enhanced by nicotine administration in wild-type littermates and in alpha7 nAChR subunit knockout mice. Nicotine 75-83 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 138-143 17135361-5 2007 RNA interference experiments show that the above nicotine-mediated process requires alpha7 nAChR. Nicotine 49-57 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 84-96 16934231-4 2006 Nicotine (0.625, 1.25, 2.5, 5 ng; ICB) markedly attenuated Delta(9)-THC ataxia dose dependently, which was abolished by ICB hexamethonium (5 microg), thus suggesting that the attenuation by nicotine occurred via the nicotinic acetylcholine receptor (nAChR). Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 250-255 16934231-9 2006 Additionally, ICB treatment with DHbetaE virtually abolished nicotine-induced attenuation of Delta(9)-THC ataxia that suggested alpha(4)beta(2) as the primary cerebellar nAChR subtype. Nicotine 61-69 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 170-175 16772172-3 2006 We recorded, in vivo, the spontaneous activity of dopaminergic neurons in the VTA of anaesthetized wt and nAChR knockout mice and their response to nicotine injections. Nicotine 148-156 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 106-111 16792571-10 2006 Intracerebellar pretreatment with hexamethonium, a nicotinic receptor (nAChR) antagonist, significantly blocked nicotine-induced attenuation of ethanol ataxia suggesting participation of nAChRs. Nicotine 112-120 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 71-76 16767415-2 2006 This effect of nicotine has been attributed to activation of the alpha7 nicotinic acetylcholine receptor (nAChR) subtype. Nicotine 15-23 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 106-111 16767415-3 2006 OBJECTIVE: The aim of this study was to determine whether the activation of another nAChR subtype, the central nervous system (CNS) prominent alpha4beta2 receptor, also contributes to the effects of nicotine on sensory gating in DBA/2 mice. Nicotine 199-207 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 84-89 16767415-11 2006 However, under conditions where alpha4beta2 receptors are blocked, nicotine still lowers T:C ratios and may improve sensory gating, possibly through the activation of other nAChR subtypes such as alpha7. Nicotine 67-75 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 173-178 16622038-0 2006 Differential regulation of mesolimbic alpha 3/alpha 6 beta 2 and alpha 4 beta 2 nicotinic acetylcholine receptor sites and function after long-term oral nicotine to monkeys. Nicotine 153-161 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 80-112 16622038-6 2006 Chronic nicotine treatment, which led to plasma nicotine levels in the range of smokers, significantly increased nucleus accumbens alpha4beta2* nAChR sites and function compared with control. Nicotine 8-16 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 144-149 16622038-6 2006 Chronic nicotine treatment, which led to plasma nicotine levels in the range of smokers, significantly increased nucleus accumbens alpha4beta2* nAChR sites and function compared with control. Nicotine 48-56 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 144-149 16622038-8 2006 Thus, these data are distinct from previous results in striatum in which the same nicotine treatment paradigm decreased striatal alpha3/alpha6beta2* nAChR sites and function. Nicotine 82-90 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 149-154 16622038-9 2006 The finding that long-term nicotine treatment selectively modulates alpha4beta2* and not alpha3/alpha6beta2* nAChR expression in primate nucleus accumbens is consistent with the results of studies in nicotinic receptor mutant mice implicating the alpha4beta2* nAChR subtype in nicotine-mediated addiction. Nicotine 27-35 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 109-114 16622038-9 2006 The finding that long-term nicotine treatment selectively modulates alpha4beta2* and not alpha3/alpha6beta2* nAChR expression in primate nucleus accumbens is consistent with the results of studies in nicotinic receptor mutant mice implicating the alpha4beta2* nAChR subtype in nicotine-mediated addiction. Nicotine 27-35 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 260-265 16001112-13 2006 Changes in nicotine sensitivity occurred both in the presence (beta2+/+) and absence (beta2-/-) of beta2* nAChRs and suggest that mechanisms involving both beta2* and non-beta2* nAChR subtypes modulate adaptation to chronic nicotine exposure. Nicotine 11-19 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 106-111 16416156-0 2006 The beta2 but not alpha7 subunit of the nicotinic acetylcholine receptor is required for nicotine-conditioned place preference in mice. Nicotine 89-97 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 40-72 16416156-7 2006 RESULTS: We have demonstrated that a pretreatment with the alpha4beta2 subunit of the nicotinic acetylcholine receptor (nAChR) antagonist dihydro-beta-erythroidine (2.0 mg/kg, s.c.) blocked nicotine (0.5 mg/kg, s.c.) CPP in wild-type mice (C57BL/6 mice). Nicotine 190-198 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 86-118 16416156-7 2006 RESULTS: We have demonstrated that a pretreatment with the alpha4beta2 subunit of the nicotinic acetylcholine receptor (nAChR) antagonist dihydro-beta-erythroidine (2.0 mg/kg, s.c.) blocked nicotine (0.5 mg/kg, s.c.) CPP in wild-type mice (C57BL/6 mice). Nicotine 190-198 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 120-125 16416156-10 2006 CONCLUSION: Taken together, these data suggest that the beta2 subunit of the nAChR is critically involved in nicotine reward as measured by CPP. Nicotine 109-117 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 77-82 15925141-1 2005 Diverse physiological and pathological effects of nicotine, including the alteration of body temperature, are presumably mediated by neuronal nicotinic acetylcholine receptors (nAChR). Nicotine 50-58 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 142-175 17192639-5 2006 Western blot and autoradiographic analyses indicate that the alpha7 nAChR subunit protein is up-regulated in human brain samples from Alzheimer patients, as well as in animal models of AD (Dineley et al., 2001; Bednar et al., 2002), and might be involved in nicotine-mediated reduction of Abeta1-42 deposition (Hellstrom et al., 2004), although the nature of this relationship remains ill-defined. Nicotine 258-266 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 61-73 15925141-1 2005 Diverse physiological and pathological effects of nicotine, including the alteration of body temperature, are presumably mediated by neuronal nicotinic acetylcholine receptors (nAChR). Nicotine 50-58 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 177-182 15925141-2 2005 Previous studies have suggested the involvement of distinct nAChR subunits in nicotine-induced thermoregulation. Nicotine 78-86 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 60-65 15925141-7 2005 These findings suggest the involvement of the beta4 nAChR subunit in both core body temperature homeostasis and nicotine-elicited thermo-alterations in mice. Nicotine 112-120 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 52-57 15723228-0 2005 Tolerance to nicotine in mice lacking alpha7 nicotinic receptors. Nicotine 13-21 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 38-44 15764844-4 2005 Both DBI levels and [(45)Ca(2+)] influx significantly increased in the brain from mice treated with nicotine for long term, which was further enhanced after abrupt cessation of nicotine and was abolished by nicotinic acetylcholine receptor (nAChR) antagonists. Nicotine 100-108 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 207-239 15896732-0 2005 Nicotine physical dependence in the mouse: involvement of the alpha7 nicotinic receptor subtype. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 62-87 15896732-5 2005 These results indicate that the alpha7 nicotinic receptor subunit may mediate some aspects of nicotine dependence. Nicotine 94-102 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 32-57 15926916-5 2005 The purpose of these studies was to clarify the effects of chronic nicotine treatment on the localization of beta2 and alpha7 nAChR subunits in brain areas involved in nicotine addiction. Nicotine 67-75 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 119-131 15926916-5 2005 The purpose of these studies was to clarify the effects of chronic nicotine treatment on the localization of beta2 and alpha7 nAChR subunits in brain areas involved in nicotine addiction. Nicotine 168-176 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 119-131 15926916-7 2005 At the end of chronic nicotine treatment the localization of the nAChR subunits was studied in the dorsal striatum and in the ventral tegmental area (VTA) by using electron microscopy. Nicotine 22-30 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 65-70 15926916-10 2005 In response to chronic nicotine treatment the beta2 and alpha7 nAChR subunit labelling was increased at synaptic and extrasynaptic sites as well as intracellularly. Nicotine 23-31 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 56-68 15926916-11 2005 This suggests that the trafficking of nAChR subunits is increased as a result of chronic nicotine treatment and nAChRs in all parts of neurons could have functional roles in the formation of nicotine addiction. Nicotine 89-97 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 38-43 15926916-11 2005 This suggests that the trafficking of nAChR subunits is increased as a result of chronic nicotine treatment and nAChRs in all parts of neurons could have functional roles in the formation of nicotine addiction. Nicotine 191-199 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 38-43 15681595-2 2005 The effect of nicotine treatment on nAChR subtypes has been extensively investigated, with the exception of changes in alpha-conotoxin MII-sensitive receptor expression. Nicotine 14-22 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 36-41 15681595-7 2005 This decline was more robust in older (>8-month-old) compared with younger (2-4-month-old) mice, suggesting age is important for nicotine-induced disruption of nAChR phenotype. Nicotine 132-140 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 163-168 15681595-8 2005 Immunoprecipitation experiments using nAChR subunit-directed antibodies indicate that alterations in subunit-immunoreactivity with nicotine treatment agree with those in the receptor binding studies. Nicotine 131-139 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 38-43 15681595-11 2005 These results may explain previous findings that nicotine treatment decreased striatal nAChR-mediated dopamine function, despite an increase in [3H]nicotine (alpha4*) sites. Nicotine 49-57 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 87-92 15738419-7 2005 We propose that the underlying mechanisms of nicotine"s detrimental side effects on a range of crucial defensive reflexes involve loss of function of nAChR subtypes, possibly via activity-dependent desensitization. Nicotine 45-53 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 150-155 15681595-12 2005 The present data suggest that the alpha6* nAChR subtype represents a key factor in the control of dopamine release from striatum, which adapts to long-term nicotine treatment by down-regulation of alpha6* receptor sites and function. Nicotine 156-164 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 42-47 15551346-5 2005 Nicotine and NS398 co-administration abolished the NS398-related effect on nAChR alpha4 retention. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 75-80 15764844-4 2005 Both DBI levels and [(45)Ca(2+)] influx significantly increased in the brain from mice treated with nicotine for long term, which was further enhanced after abrupt cessation of nicotine and was abolished by nicotinic acetylcholine receptor (nAChR) antagonists. Nicotine 100-108 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 241-246 15383622-2 2004 Here, we show that up-regulation of specific nAChR subunits takes place in white blood cells (WBCs) of smokers and mice subjected to long-term administration of nicotine. Nicotine 161-169 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 45-50 15356218-5 2005 In oocytes expressing various neuronal acetylcholine nicotinic receptors (nAChR), dextrometorphan and dextrorphan blocked nicotine activation of expressed alpha(3)beta(4), alpha(4)beta(2), and alpha(7) subtypes with a small degree of selectivity. Nicotine 122-130 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 74-79 15617730-9 2005 These results suggest a possible interaction of corticosterone and nicotine at the level of the alpha4- and alpha7-type nAChR in the regulation of PPI. Nicotine 67-75 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 120-125 15111021-1 2004 Nicotinic cholinergic receptor (nAChR) sites that bind nicotine with high affinity (likely alpha4beta2-nAChR) increase following chronic nicotine treatment. Nicotine 55-63 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 32-37 15155845-1 2004 Pharmacological evaluation of nicotine-stimulated dopamine release from striatum has yielded data consistent with activation of a single population of nicotinic acetylcholine receptors (nAChR). Nicotine 30-38 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 151-184 15155845-1 2004 Pharmacological evaluation of nicotine-stimulated dopamine release from striatum has yielded data consistent with activation of a single population of nicotinic acetylcholine receptors (nAChR). Nicotine 30-38 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 186-191 32585787-1 2004 Nicotinic cholinergic receptor (nAChR) sites that bind nicotine with high affinity (likely alpha4beta2-nAChR) increase following chronic nicotine treatment. Nicotine 55-63 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 32-37 32585787-1 2004 Nicotinic cholinergic receptor (nAChR) sites that bind nicotine with high affinity (likely alpha4beta2-nAChR) increase following chronic nicotine treatment. Nicotine 55-63 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 103-108 32585787-1 2004 Nicotinic cholinergic receptor (nAChR) sites that bind nicotine with high affinity (likely alpha4beta2-nAChR) increase following chronic nicotine treatment. Nicotine 137-145 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 32-37 32585787-1 2004 Nicotinic cholinergic receptor (nAChR) sites that bind nicotine with high affinity (likely alpha4beta2-nAChR) increase following chronic nicotine treatment. Nicotine 137-145 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 103-108 32585787-6 2004 As anticipated, likely alpha4beta2-nAChR [125I]-epibatidine binding sites increased with treatment (estimated dosage for one-half maximal increase was 0.44 mg/kg/h, plasma nicotine 20 ng/ml). Nicotine 172-180 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 35-40 15111021-1 2004 Nicotinic cholinergic receptor (nAChR) sites that bind nicotine with high affinity (likely alpha4beta2-nAChR) increase following chronic nicotine treatment. Nicotine 55-63 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 103-108 15111021-1 2004 Nicotinic cholinergic receptor (nAChR) sites that bind nicotine with high affinity (likely alpha4beta2-nAChR) increase following chronic nicotine treatment. Nicotine 137-145 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 32-37 15111021-1 2004 Nicotinic cholinergic receptor (nAChR) sites that bind nicotine with high affinity (likely alpha4beta2-nAChR) increase following chronic nicotine treatment. Nicotine 137-145 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 103-108 15111021-6 2004 As anticipated, likely alpha4beta2-nAChR [125I]-epibatidine binding sites increased with treatment (estimated dosage for one-half maximal increase was 0.44 mg/kg/h, plasma nicotine approximately 20 ng/ml). Nicotine 172-180 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 35-40 14982698-1 2004 The nicotinic acetylcholine receptor (nAChR) subtypes alpha4beta2 and alpha7 comprise the majority of brain nicotine-binding sites. Nicotine 108-116 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 70-76 15147304-6 2004 Both these observations suggest that the reduction in insoluble A beta by nicotine might be in part mediated via the alpha 7 nicotinic receptor. Nicotine 74-82 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 117-143 15136639-13 2004 Furthermore, preinjection of nAChR-binding ligands, (-)-nicotine and (-)-cytisine, reduced the uptake of (11)C-5MA in brain regions of high uptake in the untreated experiment. Nicotine 52-64 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 29-34 14996991-4 2004 Using transgenic mice with mutations in nAChR subunits, it was demonstrated previously that the alpha4-, alpha5-, and alpha7-subunits are involved in nicotine-induced seizures. Nicotine 150-158 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 40-45 14996991-7 2004 We also generated mice with double deficiency of both alpha5- and beta4-nAChR subunits and demonstrated that they were more resistant to nicotine"s convulsant effect than either the alpha5 or the beta4 single mutant mice. Nicotine 137-145 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 72-77 14762152-3 2004 The nicotine response was blocked by d-tubocurarine and mecamylamine but not alpha-bungarotoxin, indicating the presence of calcium permeable, non-alpha7 nicotinic acetylcholine receptor (nAChR) subtype. Nicotine 4-12 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 188-193 14762152-4 2004 Agonist efficacy order for eliciting the axonal nAChR calcium response was cytisine approximately nicotine >> acetylcholine. Nicotine 98-106 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 48-53 14970827-0 2004 Nicotine improves sustained attention in mice: evidence for involvement of the alpha7 nicotinic acetylcholine receptor. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 86-118 14970827-10 2004 Furthermore, as alpha7 KO mice are clearly impaired in the acquisition and asymptotic performance of this task, the alpha7 nAChR may be involved in mediating these effects of nicotine. Nicotine 175-183 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 116-128 14982698-5 2004 Following nicotine injection, dose-dependent decreases in body temperature and locomotor activity were observed for all three genotypes of both beta2 and alpha7 mice. Nicotine 10-18 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 154-160 14681928-6 2004 Collectively, these results suggest that the unique functional and pharmacological properties exerted by nAChRbeta4 on nAChR function could modify and specialize the development of strain-specific sensory and hippocampal-related characteristics of nicotine sensitivity including the development of tolerance. Nicotine 248-256 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 105-110 15464132-5 2004 Knockout mice lacking the beta2 subunit of the nAChR did not show locomotor activation in response to chronic nicotine exposure, suggesting that beta2* nAChRs are critical for ongoing activation of the dopamine system by chronic nicotine administration and the resulting locomotor activation in mice. Nicotine 229-237 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 47-52 14622092-7 2003 Therefore, the neuroprotective effects of nicotine against differing toxic assaults requires distinct nAChR subtypes and proceeds through intracellular pathways that overlap with similarly different mechanisms initiated by pro-inflammatory cytokines. Nicotine 42-50 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 102-107 14622092-2 2003 Nicotine-induced neuroprotection against different toxins is imparted through pharmacologically distinct neuronal nicotinic acetylcholine receptors (nAChR) where protection against chronic N-methyl-d-aspartic acid (NMDA) exposure is through nAChRalpha7 but protection against the toxic peptide of amyloid precursor protein, Abeta25-35, is through nAChRalpha4beta2. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 114-147 14622092-2 2003 Nicotine-induced neuroprotection against different toxins is imparted through pharmacologically distinct neuronal nicotinic acetylcholine receptors (nAChR) where protection against chronic N-methyl-d-aspartic acid (NMDA) exposure is through nAChRalpha7 but protection against the toxic peptide of amyloid precursor protein, Abeta25-35, is through nAChRalpha4beta2. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 149-154 12460746-3 2002 This study examines the hypothesis that IMI, DNIMI, and (-)-nicotine activate the extracellular signal-regulated kinase (ERK) cascade via primary interaction with the alpha4beta2 nAChR in mouse neuroblastoma N1E-115 cells. Nicotine 56-68 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 179-184 14602824-5 2003 Pretreatment with nicotine decreased glutamate-mediated calcium influx in primary cortical cultures by 41%, an effect that was absent in cultures from knock-out mice lacking the beta2 subunit of the nAChR. Nicotine 18-26 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 199-204 14602824-9 2003 We conclude that neuroprotective effects of nicotine in cortical neurons involve both beta2- and alpha7-containing nAChRs, activation of calcineurin, and decreased intracellular calcium via L-type channels. Nicotine 44-52 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 97-103 12766617-3 2003 Mouse strains expressing the A variant have, in general, greater nAChR-mediated 86Rb+ efflux in response to nicotine than strains with the T variant. Nicotine 108-116 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 65-70 12384238-8 2002 After antagonism experiments with mecamylamine, dihydro-beta-erythroidine and methyllycaconitine, it was observed that (-)nicotine-induced analgesia was mediated through the alpha4beta2 subtype of nAChR while the (+)epibatidine-induced one was mediated through non-alpha4beta2 subtype of nAChR. Nicotine 122-130 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 197-202 12384238-8 2002 After antagonism experiments with mecamylamine, dihydro-beta-erythroidine and methyllycaconitine, it was observed that (-)nicotine-induced analgesia was mediated through the alpha4beta2 subtype of nAChR while the (+)epibatidine-induced one was mediated through non-alpha4beta2 subtype of nAChR. Nicotine 122-130 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 288-293 11790724-10 2002 Inhibition of alpha4beta2, either pharmacological (i.e., an alpha4beta2 nAChR antagonist) or molecular (beta2-/- knockout mice), abolished the protective effect of nicotine in vivo and in vitro, suggesting the involvement of alpha4beta2 nAChR in neonatal nicotine-related neuroprotection. Nicotine 164-172 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 72-77 12270632-1 2002 The role of nicotinic acetylcholine receptor (nAChR) activation in accumbal dopamine (DA) release during chronic continuous nicotine treatment was studied by in vivo microdialysis in freely-moving mice. Nicotine 124-132 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 46-51 12769607-3 2002 A deeper understanding of nicotinic cholinergic mechanisms is necessary to develop nAChR ligands that are more selective, less toxic, and more therapeutically effective than nicotine. Nicotine 174-182 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 83-88 12769607-6 2002 Mice with nAChR mutations targeted to subunits that are highly expressed in the CNS have brought insight into the nAChR mechanisms involved in nicotine addiction, analgesia, aging, and nicotine-induced behaviors. Nicotine 143-151 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 10-15 12769607-6 2002 Mice with nAChR mutations targeted to subunits that are highly expressed in the CNS have brought insight into the nAChR mechanisms involved in nicotine addiction, analgesia, aging, and nicotine-induced behaviors. Nicotine 143-151 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 114-119 12769607-6 2002 Mice with nAChR mutations targeted to subunits that are highly expressed in the CNS have brought insight into the nAChR mechanisms involved in nicotine addiction, analgesia, aging, and nicotine-induced behaviors. Nicotine 185-193 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 10-15 12769607-6 2002 Mice with nAChR mutations targeted to subunits that are highly expressed in the CNS have brought insight into the nAChR mechanisms involved in nicotine addiction, analgesia, aging, and nicotine-induced behaviors. Nicotine 185-193 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 114-119 12061141-5 2002 Thus, it is suggested that alpha 7 nAChR is involved in the attention deficit of schizophrenic patients and that alpha 4 beta 2 nAChR is related to nicotine dependence or the withdrawal symptoms. Nicotine 148-156 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 128-133 11854451-0 2002 Increased sensitivity to nicotine-induced seizures in mice expressing the L250T alpha 7 nicotinic acetylcholine receptor mutation. Nicotine 25-33 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 80-87 11854451-8 2002 Increased sensitivity to nicotine-induced seizures occurred despite a 60% decline in brain alpha 7 nAChR protein levels. Nicotine 25-33 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 91-104 11854451-10 2002 Recent data from our laboratory show that alpha 7-null mice maintain normal sensitivity to nicotine-induced seizures. Nicotine 91-99 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 42-49 11854451-11 2002 Hence, these present findings suggest that alterations in the properties rather than absence of alpha 7 nAChRs might affect the mechanisms underlying the convulsive properties of nicotine. Nicotine 179-187 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 96-103 9495872-0 1998 Sensitivity to the seizure-inducing effects of nicotine is associated with strain-specific variants of the alpha 5 and alpha 7 nicotinic receptor subunit genes. Nicotine 47-55 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 107-145 11893908-6 2002 Pretreatment with the alpha7 nicotinic receptor antagonist methyllycaconitine inhibited the seizures induced by nicotine. Nicotine 112-120 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 22-47 10235262-6 1999 The alpha4 nAChR subunit, possibly associated with the beta2 nAChR subunit, is therefore crucial for nicotine-elicited antinociception. Nicotine 101-109 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 11-16 11768168-5 1999 Use of knock-out mice lacking individual nAChR subunits has also begun to elucidate how nicotine exerts its actions from the molecular level to the behavioral level. Nicotine 88-96 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 41-46 11768168-6 1999 Experiments using mice lacking the beta2 subunit of the nAChR have shown that binding of nicotine to receptors containing this subunit is the first step in a pathway leading to increased dopamine levels in the mesolimbic dopamine system, and ultimately to the behavioral effects of nicotine in a test of nicotine reinforcement. Nicotine 89-97 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 56-61 11768168-6 1999 Experiments using mice lacking the beta2 subunit of the nAChR have shown that binding of nicotine to receptors containing this subunit is the first step in a pathway leading to increased dopamine levels in the mesolimbic dopamine system, and ultimately to the behavioral effects of nicotine in a test of nicotine reinforcement. Nicotine 282-290 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 56-61 11768168-6 1999 Experiments using mice lacking the beta2 subunit of the nAChR have shown that binding of nicotine to receptors containing this subunit is the first step in a pathway leading to increased dopamine levels in the mesolimbic dopamine system, and ultimately to the behavioral effects of nicotine in a test of nicotine reinforcement. Nicotine 282-290 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 56-61 11768168-7 1999 Mice deficient in various alpha subunits of the nAChR will identify the partners of beta2 mediating the addictive properties of nicotine. Nicotine 128-136 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 48-53 9922707-6 1999 The N-nAChR are activated by nicotine and choline, and RAMIC are antagonized by methyllycaconitine and dihydro-beta-erythroidine. Nicotine 29-37 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 6-11 9634548-8 1998 Furthermore, sustained long-term nicotine delivery may promote highly region-specific retention of nAChR expression, but only if initiated before normal age-related receptor decline. Nicotine 33-41 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 99-104 11834293-4 2002 Because alpha7-containing neuronal nicotinic acetylcholine receptors (nAChRs) represent the major binding site for alpha-BTX, mice lacking the alpha7 nAChR subunit were predicted to be less sensitive to the convulsive effects of nicotine. Nicotine 229-237 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 143-155 10602325-2 1999 The dose-response parameters of recombinant mouse adult neuromuscular acetylcholine receptor channels (nAChR) activated by carbamylcholine, nicotine, muscarine and oxotremorine were measured. Nicotine 140-148 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 103-108 10803206-6 1999 The alpha 4 nAChR is associated mainly with the beta 2 subunit, and may form a component of the nicotinic pain pathways modulating the antinociceptive effect of nicotine. Nicotine 161-169 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 12-17 9808692-11 1998 The pharmacological and regional comparisons suggest that the nAChR that stimulates [3H]-GABA release is the one that binds [3H]-nicotine with high affinity (alpha4beta2). Nicotine 129-137 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 62-67 10454356-10 1998 Future studies will examine the contribution of alpha7 nAChR to the enhancement of learning and sensorimotor gating following nicotine treatments. Nicotine 126-134 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 48-60 9749753-2 1998 The major isoform of nAChR in the brain is made up of the alpha4 and beta2 subunits and possesses a high affinity for nicotine. Nicotine 118-126 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 21-26 9627107-4 1998 Pretreatment with several different nAChR agonists (A-85380, (-)-nicotine, cytisine) significantly inhibited [I-125]-5-IA binding in all brain regions studied (P < 0.01) demonstrating the high specificity of the radioligand for nAChRs. Nicotine 61-73 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 36-41 9667769-6 1998 The nAChR agonists (-)nicotine, cytisine, and (+) epibatidine reduced the radioactivity due to [11C]A-84543 in the superior colliculus by 41%, 38%, and 27%, respectively, while lobeline, which also interacts with central nAChRs, produced a 24% inhibition. Nicotine 22-30 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 4-9 9084060-1 1997 The aim of the present study was to evaluate the effects of nicotinic acetylcholine receptor (nACh-R) agonists such as (-)-nicotine and related compounds on brain monoamine turnover. Nicotine 119-131 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 60-92 9255161-11 1997 Preinjection of blocking doses of unlabeled epibatidine, (-)-nicotine, lobeline and cytisine significantly inhibited [18F]FPH binding in thalamus and superior colliculus, but not in cerebellum, whereas drugs that interact with binding sites other than acetylcholine recognition sites of nAChR (e.g., mecamylamine, scopolamine, N-methylspiperone and ketanserin) had no effect on [18F]FPH accumulation in any of the brain regions examined. Nicotine 57-69 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 287-292 9084060-1 1997 The aim of the present study was to evaluate the effects of nicotinic acetylcholine receptor (nACh-R) agonists such as (-)-nicotine and related compounds on brain monoamine turnover. Nicotine 119-131 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 94-100 9084060-4 1997 The (-)-nicotine (1.0 mg/kg)-induced changes in monoamine turnover were blocked by pretreatment with the centrally acting nACh-R channel blocker mecamylamine (2.0 mg/kg i.p.) Nicotine 8-16 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 122-128 7870173-1 1995 Nicotine affects many aspects of behaviour including learning and memory through its interaction with neuronal nicotinic acetylcholine receptors (nAChR). Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 111-144 7542542-1 1995 The purpose of this investigation was to determine if analogous to (-)-nicotine"s analgesic effect, the analgesic effect of the recently characterized potent nicotinic acetylcholine receptor (nAChR) agonist (+/-)-epibatidine was altered in response to treatment with the calcium channel agonist (+/-)-Bay K 8644. Nicotine 67-79 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 158-190 7542542-1 1995 The purpose of this investigation was to determine if analogous to (-)-nicotine"s analgesic effect, the analgesic effect of the recently characterized potent nicotinic acetylcholine receptor (nAChR) agonist (+/-)-epibatidine was altered in response to treatment with the calcium channel agonist (+/-)-Bay K 8644. Nicotine 67-79 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 192-197 7870173-1 1995 Nicotine affects many aspects of behaviour including learning and memory through its interaction with neuronal nicotinic acetylcholine receptors (nAChR). Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 146-151 35111269-8 2022 Result: We found that nicotine exposure stimulated the HCC tumorigenicity by inducing the expression of one of the key nAChRs subunit that is alpha7nAChR as well as the expression of Janus kinase (JAK)-2. Nicotine 22-30 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 142-153 10947823-4 2000 This nicotinic response was almost completely absent in beta2-/- mutant mice, leaving a small residual response to a high concentration (100 microM) of nicotine which was inhibited by the alpha7-subunit-selective antagonist, methyllycaconitine. Nicotine 152-160 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 188-194 10947823-8 2000 These results demonstrate that in nigral dopaminergic neurons, nicotine can elicit Ca2+ mobilization via activation of two distinct nAChR subtypes: that of beta2-subunit-containing nAChR followed by activation of Na+ channel and T-type Ca2+ channels, and/or activation of alpha7-subunit-containing nAChR. Nicotine 63-71 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 132-137 10947823-8 2000 These results demonstrate that in nigral dopaminergic neurons, nicotine can elicit Ca2+ mobilization via activation of two distinct nAChR subtypes: that of beta2-subunit-containing nAChR followed by activation of Na+ channel and T-type Ca2+ channels, and/or activation of alpha7-subunit-containing nAChR. Nicotine 63-71 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 181-186 10947823-8 2000 These results demonstrate that in nigral dopaminergic neurons, nicotine can elicit Ca2+ mobilization via activation of two distinct nAChR subtypes: that of beta2-subunit-containing nAChR followed by activation of Na+ channel and T-type Ca2+ channels, and/or activation of alpha7-subunit-containing nAChR. Nicotine 63-71 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 272-278 10947823-8 2000 These results demonstrate that in nigral dopaminergic neurons, nicotine can elicit Ca2+ mobilization via activation of two distinct nAChR subtypes: that of beta2-subunit-containing nAChR followed by activation of Na+ channel and T-type Ca2+ channels, and/or activation of alpha7-subunit-containing nAChR. Nicotine 63-71 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 181-186 33819533-9 2021 Our findings suggest that habitual smoking in SCZ might be attributed to get therapeutic and reduce side effects mediated by alpha7 and alpha4beta2 nAChR activation by (-)-NIC. Nicotine 172-175 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 148-153 19170184-7 2009 In addition, nanomolar concentrations of nicotine, which did not induce any response in these cells, largely desensitized nAChR-mediated currents. Nicotine 41-49 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 122-127 34490270-0 2021 alpha1-nAchR-Mediated Signaling Through Lipid Raft Is Required for Nicotine-Induced NLRP3 Inflammasome Activation and Nicotine-Accelerated Atherosclerosis. Nicotine 67-75 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 7-12 34490270-0 2021 alpha1-nAchR-Mediated Signaling Through Lipid Raft Is Required for Nicotine-Induced NLRP3 Inflammasome Activation and Nicotine-Accelerated Atherosclerosis. Nicotine 118-126 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 7-12 34490270-7 2021 Mechanically, nicotine increased the expression of alpha1-nAChR and stimulated the accumulation of alpha1-nAChR in lipid raft, leading to NLRP3 inflammasome activation in macrophage. Nicotine 14-22 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 106-111 34490270-8 2021 Conversely, silencing of alpha1-nAChR in macrophage sufficiently blocked the pro-inflammasome activation effect of nicotine, indicating that alpha1-nAChR was the specific receptor for nicotine in triggering NLRP3 inflammasome in macrophage. Nicotine 115-123 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 148-153 34490270-8 2021 Conversely, silencing of alpha1-nAChR in macrophage sufficiently blocked the pro-inflammasome activation effect of nicotine, indicating that alpha1-nAChR was the specific receptor for nicotine in triggering NLRP3 inflammasome in macrophage. Nicotine 184-192 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 148-153 34490270-9 2021 Furthermore, both the destruction of lipid raft by methyl-beta-cyclodextrin and the interference of lipid raft clustering by silencing acid sphingomyelinase reversed nicotine-induced NLRP3 inflammasome activation by reducing the accumulation of alpha1-nAChR in lipid raft in macrophage, suggesting lipid raft-mediated accumulation of alpha1-nAChR was the key event in regulating the pro-inflammatory effects of nicotine in macrophage. Nicotine 166-174 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 341-346 34490270-9 2021 Furthermore, both the destruction of lipid raft by methyl-beta-cyclodextrin and the interference of lipid raft clustering by silencing acid sphingomyelinase reversed nicotine-induced NLRP3 inflammasome activation by reducing the accumulation of alpha1-nAChR in lipid raft in macrophage, suggesting lipid raft-mediated accumulation of alpha1-nAChR was the key event in regulating the pro-inflammatory effects of nicotine in macrophage. Nicotine 411-419 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 341-346 34490270-11 2021 Conclusion: alpha1-nAChR-mediated signaling through lipid raft is required for NLRP3 inflammasome activation and pro-atherosclerotic property of nicotine. Nicotine 145-153 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 19-24 34440849-11 2021 Mechanistically, we observed that nicotine regulated YAP nuclear translocation and its interaction with TEAD through alpha7-nAChR-Akt signaling, subsequently resulting in increased TEAD occupancy on the HSPA5 promoter and elevated promoter activity. Nicotine 34-42 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 117-129 34193682-5 2021 Intra-mPFC infusion of mecamylamine, a non-selective nicotinic acetylcholine receptor (nAChR) antagonist, 5 min before nicotine administration blocked the effect of nicotine. Nicotine 165-173 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 53-85 34193682-5 2021 Intra-mPFC infusion of mecamylamine, a non-selective nicotinic acetylcholine receptor (nAChR) antagonist, 5 min before nicotine administration blocked the effect of nicotine. Nicotine 165-173 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 87-92 34193682-6 2021 Additionally, intra-mPFC infusion of dihydro-beta-erythroidine, a selective alpha4beta2 nAChR antagonist, or methyllycaconitine, a selective alpha7 nAChR antagonist, significantly suppressed the nicotine-induced object recognition memory enhancement. Nicotine 195-203 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 88-93 34193682-6 2021 Additionally, intra-mPFC infusion of dihydro-beta-erythroidine, a selective alpha4beta2 nAChR antagonist, or methyllycaconitine, a selective alpha7 nAChR antagonist, significantly suppressed the nicotine-induced object recognition memory enhancement. Nicotine 195-203 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 141-153 35231469-4 2022 Nicotine-induced depression in sensory stimulation-evoked MLI-PC synaptic transmission was abolished by either a non-selective nAChR blocker, hexamethonium, or the alpha7-nAChR antagonist methyllycaconitine (MLA), but not the selective alpha4beta2-nAChR antagonist dihydro-beta-erythroidine. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 127-132 35231469-4 2022 Nicotine-induced depression in sensory stimulation-evoked MLI-PC synaptic transmission was abolished by either a non-selective nAChR blocker, hexamethonium, or the alpha7-nAChR antagonist methyllycaconitine (MLA), but not the selective alpha4beta2-nAChR antagonist dihydro-beta-erythroidine. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 164-176 35231469-4 2022 Nicotine-induced depression in sensory stimulation-evoked MLI-PC synaptic transmission was abolished by either a non-selective nAChR blocker, hexamethonium, or the alpha7-nAChR antagonist methyllycaconitine (MLA), but not the selective alpha4beta2-nAChR antagonist dihydro-beta-erythroidine. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 248-253 35111269-12 2022 Conclusions: Taken together, the presented results indicate the positive effect of inhibition of nicotine induced overexpression of alpha7nAChR and JAK2, unique to HCC. Nicotine 97-105 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 132-143 35111269-13 2022 Thus, these findings suggest the nicotine effect on HCC progression via alpha7nAChR-mediated JAK2 signaling pathways, and DHCT treatment enhances the therapeutic potential of HCC patients via overcoming/reversing the effect of nicotine in HCC patients. Nicotine 33-41 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 72-83 33607168-9 2021 Methyllycaconitine (an alpha7nAChR antagonist) antagonized the effect of nicotine on decreased social interaction time and prolonged immobility in the forced swimming test, but not increased locomotor activity. Nicotine 73-81 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 23-34 34997096-5 2022 2-deoxy-D-glucose, a central vagal stimulant suppressed OXZ colitis, and nicotine also ameliorated OXZ colitis with suppressing Th2 cytokines, which was reversed by alpha7nAChR antagonist methyllycaconitine. Nicotine 73-81 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 165-176 33878302-1 2021 The low sensitivity (alpha4)3(beta2)2 (LS) and high sensitivity (alpha4)2(beta2)3 (HS) nAChR isoforms may contribute to a variety of brain functions, pathophysiological processes, and pharmacological effects associated with nicotine use. Nicotine 224-232 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 87-92 33878302-8 2021 Therefore, these results indicate a more prevalent role of HS alpha4beta2 nAChR isoforms in mediating various behavioral effects associated with nicotine, whereas the LS alpha4beta2 nAChR isoform has a limited role in mediating body temperature and nociceptive responses. Nicotine 145-153 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 74-79 33878302-9 2021 These findings will facilitate the development of more selective, efficacious, and safe nAChR-based therapeutics for nicotine addiction treatment. Nicotine 117-125 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 88-93 34038754-5 2021 Nicotine withdrawal symptoms were precipitated by an acute injection of mecamylamine, a nonspecific nAChR antagonist, following chronic nicotine consumption. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 100-105 33607168-12 2021 The ameliorating effects of nicotine and galantamine on depression-like behaviors in KMO KO mice are associated with the activation of alpha7nAChR. Nicotine 28-36 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 135-146 33326305-9 2021 DC-shifts were produced via nAChRs on primary afferents: they were also seen with nAChR agonists (epibatidine and nicotine), blocked with D-TC but not GABAA receptor blockers, and retained after block of voltage-gated Na+ channels. Nicotine 114-122 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 28-33 33851731-5 2021 Blocking nAChR activity with an antagonist completely abolishes nicotine"s influence on astrocyte morphology indicating that nicotine"s action is mediated by these receptors. Nicotine 64-72 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 9-14 33851731-5 2021 Blocking nAChR activity with an antagonist completely abolishes nicotine"s influence on astrocyte morphology indicating that nicotine"s action is mediated by these receptors. Nicotine 125-133 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 9-14 33603170-3 2021 Here we report that nicotine enhances ESCC cancer malignancy and tumor-initiating capacity by interacting with cholinergic receptor nicotinic alpha 7 subunit (CHRNA7) and subsequently activating the JAK2/STAT3 signaling pathway. Nicotine 20-28 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 159-165 33603170-6 2021 Mechanistically, dextromethorphan non-competitively inhibited nicotine binding to CHRNA7 while metformin downregulated CHRNA7 expression by antagonizing nicotine-induced promoter DNA hypomethylation of CHRNA7. Nicotine 62-70 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 82-88 33603170-6 2021 Mechanistically, dextromethorphan non-competitively inhibited nicotine binding to CHRNA7 while metformin downregulated CHRNA7 expression by antagonizing nicotine-induced promoter DNA hypomethylation of CHRNA7. Nicotine 153-161 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 119-125 33603170-6 2021 Mechanistically, dextromethorphan non-competitively inhibited nicotine binding to CHRNA7 while metformin downregulated CHRNA7 expression by antagonizing nicotine-induced promoter DNA hypomethylation of CHRNA7. Nicotine 153-161 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 119-125 33995360-4 2021 Then, we further investigated the regulatory role of alpha7nAChR activation by nicotine on decidual macrophage polarization and placental remodeling in the PE-like mouse model. Nicotine 79-87 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 53-64 33995360-12 2021 alpha-bungarotoxin (alpha-BGT) which is specific antagonist for alpha7nAChR could abolish the effects of nicotine on decidual macrophage polarization, trophoblast arrangement and vascular structure in placental tissue in PE mice. Nicotine 105-113 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 64-75 32726882-3 2021 alpha7 nicotinic acetylcholine receptor (alpha7 nAChR), as a receptor of nicotine and its metabolites, is a potential target for lung cancer treatment. Nicotine 73-81 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 41-53 32815115-2 2020 Two major functional subtypes of nAChR in the brain, alpha7-type and alpha4beta2-type, have a high affinity for nicotine. Nicotine 112-120 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 33-38 33440720-1 2021 The nicotinic acetylcholine receptor (nAChR) is one of the receptors of acetylcholine (ACh), and nicotine (NIC) acts as an agonist of this receptor. Nicotine 97-105 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 4-36 33440720-1 2021 The nicotinic acetylcholine receptor (nAChR) is one of the receptors of acetylcholine (ACh), and nicotine (NIC) acts as an agonist of this receptor. Nicotine 97-105 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 38-43 33440720-1 2021 The nicotinic acetylcholine receptor (nAChR) is one of the receptors of acetylcholine (ACh), and nicotine (NIC) acts as an agonist of this receptor. Nicotine 107-110 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 4-36 33440720-1 2021 The nicotinic acetylcholine receptor (nAChR) is one of the receptors of acetylcholine (ACh), and nicotine (NIC) acts as an agonist of this receptor. Nicotine 107-110 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 38-43 33109433-7 2020 These effects of (-)-NIC were completely blocked by both methyllycaconitine, a selective alpha7 nAChR antagonist, and dihydro-beta-erythroidine (DHbetaE), a selective alpha4beta2 nAChR antagonist. Nicotine 21-24 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 89-101 33109433-7 2020 These effects of (-)-NIC were completely blocked by both methyllycaconitine, a selective alpha7 nAChR antagonist, and dihydro-beta-erythroidine (DHbetaE), a selective alpha4beta2 nAChR antagonist. Nicotine 21-24 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 96-101 33109433-9 2020 These findings suggest that alpha7 nAChR is associated with development of disease and is implicated in the therapeutic effect of nicotine in SCZ. Nicotine 130-138 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 28-40 33952828-7 2021 The effect of nicotine was blocked by the alpha4beta2 nicotinic acetylcholine receptor (nAChR) antagonist dihydro-beta-erythroidine, alpha7 nAChR antagonist methyllycaconitine, or intracellular perfusion with the Ca2+ chelator 1,2-bis(2-aminophenoxy)ethane-N,N,N",N"-tetraacetic acid (BAPTA). Nicotine 14-22 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 88-93 33952828-7 2021 The effect of nicotine was blocked by the alpha4beta2 nicotinic acetylcholine receptor (nAChR) antagonist dihydro-beta-erythroidine, alpha7 nAChR antagonist methyllycaconitine, or intracellular perfusion with the Ca2+ chelator 1,2-bis(2-aminophenoxy)ethane-N,N,N",N"-tetraacetic acid (BAPTA). Nicotine 14-22 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 133-145 32927162-12 2021 The alpha7 nAChR specific antagonist abrogated nicotine-induced AMPK phosphorylation and autophagy initiation. Nicotine 47-55 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 4-16 33339145-2 2020 The alpha3beta4 nicotinic acetylcholine receptor (nAChR) is strongly associated with nicotine reward and withdrawal symptom. Nicotine 85-93 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 50-55 33339145-5 2020 The present experiment investigates the effect of alpha3beta4 nAChR antagonists (TxID and [S9K]TxID) on the expression and reinstatement of nicotine-induced conditioned place preference (CPP) and explores the behaviors of acute nicotine in mice. Nicotine 140-148 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 62-67 33339145-8 2020 Therefore, these findings reveal that the alpha3beta4 nAChR may be a potential target for anti-nicotine addiction treatment. Nicotine 95-103 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 54-59 33414685-12 2020 Scratch-wound assay showed marked reduction in proliferation/migration of nicotine and palmitate-treated breast cancer cells with mecamylamine (MEC), a nicotine acetylcholine receptor (nAchR) antagonist. Nicotine 74-82 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 152-183 33414685-12 2020 Scratch-wound assay showed marked reduction in proliferation/migration of nicotine and palmitate-treated breast cancer cells with mecamylamine (MEC), a nicotine acetylcholine receptor (nAchR) antagonist. Nicotine 74-82 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 185-190 32959891-7 2020 KEY RESULTS: Apical application of the nAChR agonist nicotine transiently increased ISC (EC50 : 19.83 mumol*L-1 ). Nicotine 53-61 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 39-44 32959891-8 2020 The nicotine-effect was abolished by the nAChR inhibitor mecamylamine. Nicotine 4-12 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 41-46 32959891-15 2020 CONCLUSIONS AND IMPLICATIONS: alpha3beta4 nAChR are responsible for the nicotine-induced current changes via Ca2+ -release from intracellular stores, PKA and ryanodine receptor activation. Nicotine 72-80 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 42-47 32815115-4 2020 Chronic exposure to nicotine together with methyllycaconitine, an alpha7-type nAChR antagonist, but not with dihydro-beta-erythroidine, an alpha4beta2-type nAChR antagonist, failed to rescue the depressive-like behavior and restore the reduced number of BrdU-positive cells in the dentate gyrus (DG) of CaMKIV null mice. Nicotine 20-28 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 78-83 32815115-6 2020 Similar to chronic exposure to nicotine, both PNU-282987 and GTS-21, alpha7-type nAChR agonists, significantly rescued depressive-like behavior, with a reduction in the number of BrdU-positive cells in the DG of CaMKIV null mice. Nicotine 31-39 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 81-86 32815115-8 2020 Taken together, we demonstrated that chronic exposure to nicotine rescues depressive-like behavior via alpha7-type nAChR through the activation of both PI3K/Akt and ERK/CREB pathways in CaMKIV null mice. Nicotine 57-65 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 115-120 32988984-1 2020 Previous reports indicate that nicotine reward is mediated through alpha4beta2*, alpha6beta2*, and alpha4alpha6beta2* nicotinic acetylcholine receptors (nAChRs) (*, indicates that additional nAChR subunits may be present). Nicotine 31-39 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 153-158 33328880-0 2020 Nicotine Prevents Oxidative Stress-Induced Hippocampal Neuronal Injury Through alpha7-nAChR/Erk1/2 Signaling Pathway. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 79-91 33328880-12 2020 Taken together, our findings suggest that nicotine suppresses H2O2-induced HT-22 cell injury through activating the alpha7-nAChR/Erk1/2 signaling pathway, which indicates that nicotine may be a novel strategy for the treatment of neurodegenerative disorders. Nicotine 42-50 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 116-128 33328880-12 2020 Taken together, our findings suggest that nicotine suppresses H2O2-induced HT-22 cell injury through activating the alpha7-nAChR/Erk1/2 signaling pathway, which indicates that nicotine may be a novel strategy for the treatment of neurodegenerative disorders. Nicotine 176-184 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 116-128 33074245-5 2020 This nAChR is a candidate for the analgesic effects of nicotine as well as the frog toxin epibatidine. Nicotine 55-63 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 5-10 32988984-3 2020 Here we use male and female mice that contain alpha4-mCherry and alpha6-GFP nAChR subunits to show that concentrations of nicotine sufficient to evoke reward-related behavior robustly upregulate alpha4* and alpha4alpha6* nAChRs on midbrain dopamine (DA) and gamma-aminobutyric acid (GABA) neurons. Nicotine 122-130 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 76-81 32988984-4 2020 Furthermore, the extent of alpha4alpha6* nAChR upregulation on ventral tegmental area (VTA) DA neurons aligns with the magnitude of nicotine reward-related behavior. Nicotine 132-140 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 41-46 32568759-1 2020 The diversity of nicotinic cholinergic receptor (nAChR) subunits underlies the complex responses to nicotine. Nicotine 100-108 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 49-54 32568759-3 2020 Deletion or partial deletion of the alpha4, beta2 or both nAChR subunits reduced the sensitivity of mice to acute nicotine administration. Nicotine 114-122 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 58-63 32568759-12 2020 However, following chronic treatment with 4.0 mg/kg/h nicotine, wild type, alpha4 and alpha4 mice displayed increased Y-maze crossings following acute administration of 0.5 mg/kg nicotine that may reflect the activity of alpha6beta2*-nAChR. Nicotine 54-62 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 234-239 32568759-12 2020 However, following chronic treatment with 4.0 mg/kg/h nicotine, wild type, alpha4 and alpha4 mice displayed increased Y-maze crossings following acute administration of 0.5 mg/kg nicotine that may reflect the activity of alpha6beta2*-nAChR. Nicotine 179-187 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 234-239 32691528-8 2020 Furthermore, the nonselective nAChR antagonist, mecamylamine, reversed nicotine effects on sociability and increased repetitive behaviors in BTBR T + tf/J mice. Nicotine 71-79 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 30-35 32747456-10 2020 Consequently, these data show that the green apple flavorant, farnesene, causes reward-related behavior without nicotine through changes in nAChR stoichiometry that results in an enhanced effect of nicotine on VTA dopamine neurons. Nicotine 198-206 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 140-145 31930655-1 2020 Recent studies have showed that alpha5 nicotinic acetylcholine receptor (alpha5-nAChR) is closely associated with nicotine-related lung cancer. Nicotine 114-122 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 80-85 32304995-0 2020 Acute nicotine administration stimulates ciliary activity via alpha3beta4 nAChR in the mouse trachea. Nicotine 6-14 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 74-79 32304995-5 2020 Nicotine-induced PTS acceleration was sensitive to the general nAChR inhibitors mecamylamine and d-tubocurarine as well as to the alpha3beta4-nAChR antagonist alpha-conotoxin AulB, but not to other antagonists primarily addressing alpha3beta2-nAChR or alpha4-, alpha7- and alpha9-containing nAChR. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 63-68 32304995-5 2020 Nicotine-induced PTS acceleration was sensitive to the general nAChR inhibitors mecamylamine and d-tubocurarine as well as to the alpha3beta4-nAChR antagonist alpha-conotoxin AulB, but not to other antagonists primarily addressing alpha3beta2-nAChR or alpha4-, alpha7- and alpha9-containing nAChR. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 142-147 32304995-5 2020 Nicotine-induced PTS acceleration was sensitive to the general nAChR inhibitors mecamylamine and d-tubocurarine as well as to the alpha3beta4-nAChR antagonist alpha-conotoxin AulB, but not to other antagonists primarily addressing alpha3beta2-nAChR or alpha4-, alpha7- and alpha9-containing nAChR. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 142-147 32373212-11 2020 The alpha7 nicotine acetylcholine receptor (alpha7nAChR) was highly expressed in HAECs and its antagonist could effectively relieve nicotine-induced EndMT and atherosclerotic lesions in mice. Nicotine 11-19 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 44-55 32373212-11 2020 The alpha7 nicotine acetylcholine receptor (alpha7nAChR) was highly expressed in HAECs and its antagonist could effectively relieve nicotine-induced EndMT and atherosclerotic lesions in mice. Nicotine 132-140 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 44-55 32092237-0 2020 Unexpected loss of sensitivity to the nicotinic acetylcholine receptor antagonist activity of mecamylamine and dihydro-beta-erythroidine in nicotine-tolerant mice. Nicotine 140-148 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 38-70 32092237-1 2020 OBJECTIVES: There is a long-standing interest in developing nicotinic acetylcholine receptor (nAChR) antagonists for concomitant use with nAChR agonists (e.g., nicotine replacement) as complementary smoking cessation aids. Nicotine 160-168 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 60-92 32092237-2 2020 Previous studies demonstrate that daily nicotine treatment confers tolerance to some effects of nicotine, as well as cross-tolerance to other nAChR agonists. Nicotine 40-48 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 142-147 31881170-1 2020 Desensitization of the nicotinic acetylcholine receptor (nAChR) containing the beta2 subunit is a potentially critical mechanism underlying the body weight (BW) reducing effects of nicotine. Nicotine 181-189 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 23-55 31881170-1 2020 Desensitization of the nicotinic acetylcholine receptor (nAChR) containing the beta2 subunit is a potentially critical mechanism underlying the body weight (BW) reducing effects of nicotine. Nicotine 181-189 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 57-62 31813548-6 2020 Methyllycaconitine citrate (alpha7-nAChR blocker, MLA) inhibited HO-1 expression and the effects of nicotine on autophagy and apoptosis of NMCMs. Nicotine 100-108 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 28-40 31930655-2 2020 Our previous studies also demonstrated that alpha5-nAChR mediates nicotine-induced lung carcinogenesis. Nicotine 66-74 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 51-56 32468493-2 2020 After inhalation and absorption, nicotine binds to various nicotinic acetylcholine receptor (nAChR) subtypes localized on the pre- and postsynaptic membranes of cells, which subsequently leads to the modulation of cellular function and neurotransmitter signaling. Nicotine 33-41 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 59-91 32468493-2 2020 After inhalation and absorption, nicotine binds to various nicotinic acetylcholine receptor (nAChR) subtypes localized on the pre- and postsynaptic membranes of cells, which subsequently leads to the modulation of cellular function and neurotransmitter signaling. Nicotine 33-41 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 93-98 32468493-3 2020 In this chapter, we begin by briefly reviewing the current understanding of nicotine"s actions on nAChRs and highlight considerations regarding nAChR subtype localization and pharmacodynamics. Nicotine 76-84 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 98-103 31835083-8 2020 Additionally, the expression of alpha7-nAChR on KCs was dramatically increased by nicotine treatment, and the protective effects of nicotine on ConA-induced liver injury were significantly suppressed by treatment with methyllycaconitine (MLA), a specific alpha7-nAChR antagonist. Nicotine 82-90 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 32-44 31835083-10 2020 This study suggests that nicotine increases alpha7-nAChR-mediated cholinergic activity in KCs resulting in decrease of ConA-induced autoimmune hepatitis through inhibiting NF-kappaB signaling. Nicotine 25-33 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 44-56 31835083-8 2020 Additionally, the expression of alpha7-nAChR on KCs was dramatically increased by nicotine treatment, and the protective effects of nicotine on ConA-induced liver injury were significantly suppressed by treatment with methyllycaconitine (MLA), a specific alpha7-nAChR antagonist. Nicotine 132-140 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 255-267 31298524-6 2019 Both nicotine-induced upregulation and changes in nAChR stoichiometry differ across brain regions. Nicotine 5-13 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 50-55 31776253-2 2019 beta2* nicotinic acetylcholine receptors (nAChR) are necessary and sufficient for the experience of both nicotine reward and aversion in an intra-VTA (ventral tegmental area) self-administration paradigm. Nicotine 105-113 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 7-40 31776253-2 2019 beta2* nicotinic acetylcholine receptors (nAChR) are necessary and sufficient for the experience of both nicotine reward and aversion in an intra-VTA (ventral tegmental area) self-administration paradigm. Nicotine 105-113 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 42-47 31443523-0 2019 alpha-Conotoxin TxIB: A Uniquely Selective Ligand for alpha6/alpha3beta2beta3 Nicotinic Acetylcholine Receptor Attenuates Nicotine-Induced Conditioned Place Preference in Mice. Nicotine 122-130 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 78-110 31443523-9 2019 The current work described the inhibition activity of TxIB in NIC-induced CPP, suggesting that alpha6beta2* nAChR-targeted compound may be a promising drug for nicotine addiction treatment. Nicotine 62-65 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 108-113 31443523-9 2019 The current work described the inhibition activity of TxIB in NIC-induced CPP, suggesting that alpha6beta2* nAChR-targeted compound may be a promising drug for nicotine addiction treatment. Nicotine 160-168 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 108-113 31744841-9 2019 These actions of nicotine, which occurred at concentrations of nicotine found in the artificial cerebrospinal fluid of cigarette smokers, may play a role in the reward system"s adaptive response to repeated nicotine exposure.Significance Statement This study uncovers novel aspects of nAChR neuropharmacology and VTA neurobiology that have implications for understanding nicotine dependence mechanisms. Nicotine 17-25 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 285-290 31302720-1 2019 RATIONALE: The alpha7 nicotinic acetylcholine receptor (nAChR) has been implicated as a target in modulating nicotine reward. Nicotine 109-117 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 56-61 31302720-2 2019 However, the effect of pharmacological agents that have been shown to alter the channel properties of the alpha7 nAChR is not well understood in nicotine reward. Nicotine 145-153 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 106-118 31302720-3 2019 OBJECTIVES: This study aimed to investigate the impact of alpha7 nAChR pharmacological modulation on nicotine conditioned place preference (CPP) in mice by using positive allosteric modulators (PAMs) and a silent agonist. Nicotine 101-109 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 58-70 31302720-8 2019 RESULTS: The alpha7 full orthosteric agonist PNU282987 and the Type II alpha7 nAChR PAM PNU120596 reduced nicotine CPP, while the silent agonist NS6740 and Type I PAM NS1738 had no effect. Nicotine 106-114 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 78-83 31302720-10 2019 CONCLUSIONS: Taken together, our results suggest that modulation of the alpha7 nAChR can play important roles in nicotine CPP in mice. Nicotine 113-121 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 72-84 31302720-11 2019 In addition, the Type II alpha7 nAChR PAM PNU120596 attenuated nicotine reward suggesting that endogenous acetylcholine/choline tone is sufficient to reduce nicotine CPP. Nicotine 63-71 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 32-37 31302720-11 2019 In addition, the Type II alpha7 nAChR PAM PNU120596 attenuated nicotine reward suggesting that endogenous acetylcholine/choline tone is sufficient to reduce nicotine CPP. Nicotine 157-165 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 32-37 31299179-0 2019 The alpha7 nicotinic receptor silent agonist R-47 prevents and reverses paclitaxel-induced peripheral neuropathy in mice without tolerance or altering nicotine reward and withdrawal. Nicotine 151-159 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 4-29 31051233-1 2019 We recently found that in mouse dopaminergic neurons, the heteromer formed by the dopamine D3 receptor (D3R) and the beta2 subunit of acetylcholine nicotinic receptor (nAChR) exerts neurotrophic effects when activated by nicotine, leading to neurons with enlarged cell bodies and increased dendrite arborization. Nicotine 221-229 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 168-173 31051233-2 2019 Beside this action, we now show that nicotine, by activating the D3R-nAChR heteromer, protects dopaminergic neurons against neuronal injury. Nicotine 37-45 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 69-74 31051233-3 2019 In primary cultures of mouse dopaminergic neurons, in fact, the ability of nicotine to inhibit both the pathological accumulation of alpha-synuclein induced by glucose deprivation and the consequent morphological defects were strongly prevented by disrupting the D3R-nAChR heteromer with specific interfering TAT-peptides; the relevance of the phosphoinositide 3-kinase (PI3K) intracellular signaling in mediating nicotine prevention of alpha-synuclein aggregation has been also demonstrated. Nicotine 75-83 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 267-272 31051233-6 2019 In this human cell model, nicotine exerts neuroprotective effects specifically acting through the D3R-nAChR complex thus indicating that this heteromer is a relevant molecular effector involved in the protection of human dopaminergic neurons. Nicotine 26-34 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 102-107 31447654-4 2019 For understanding potential short-term and long-term effects of gestational nicotine exposure, it is important to know the temporal and spatial expression of alpha7 nAChRs throughout the body. Nicotine 76-84 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 158-164 31145916-12 2019 The results of this study will further our knowledge of the role of the beta3 nAChR subunit in nicotine reward and withdrawal behaviors in hopes of finding new molecular targets for smoking cessation aids. Nicotine 95-103 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 78-83 31145916-3 2019 The beta3 subunit of the nAChR has been understudied in nicotine dependence, even though it is expressed in brain regions important for drug reward. Nicotine 56-64 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 25-30 29864448-8 2018 alpha7-containing and beta2-containing nAChRs were involved in nicotine-induced [3H]-GABA release in control and mdx synaptosomes. Nicotine 63-71 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 0-6 31152077-7 2019 The effects of nicotine were abolished by the selective alpha7 nicotinic acetylcholine receptor (nAChR) blocker, methyllycaconitine . Nicotine 15-23 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 97-102 31152077-9 2019 In addition, nicotine significantly enhanced PI3K/Akt and inhibited NF-kappaB translocation from the cytosol to the nucleus in an alpha7-nAChR-dependent manner, suggesting that nicotine acts on alpha7-nAChRs to inhibit MMP-9 production by macrophages through modulation of the PI3K/Akt-NF-kappaB pathway. Nicotine 13-21 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 130-142 31152077-9 2019 In addition, nicotine significantly enhanced PI3K/Akt and inhibited NF-kappaB translocation from the cytosol to the nucleus in an alpha7-nAChR-dependent manner, suggesting that nicotine acts on alpha7-nAChRs to inhibit MMP-9 production by macrophages through modulation of the PI3K/Akt-NF-kappaB pathway. Nicotine 177-185 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 130-142 30354182-5 2019 Picospritzing nicotine both induced a direct inward current and increased the frequency of spontaneous excitatory postsynaptic currents (sEPSCs) in NTS-CA neurons, effects blocked by nonselective nAChR antagonists TMPH and MLA. Nicotine 14-22 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 196-201 30114604-1 2018 Nicotine, an nAChR agonist, shows prominent anti-inflammatory properties, and some studies have illustrated its suppressive effects on inflammation. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 13-18 30062776-9 2018 We observed that short- and long-term nicotine/cotinine exposure significantly decreased neuronal glucose utilization in ischemic conditions and the non-specific nAChR antagonist, mecamylamine reversed this effect. Nicotine 38-46 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 162-167 30062776-10 2018 Nicotine/cotinine exposure also decreased neuronal GLUT1 and up-regulated alpha7 nAChR expression and decreased glycolysis. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 74-86 30867261-3 2019 Using an approach involving photoactivatable nicotine, we previously demonstrated that chronic nicotine (cNIC) potently enhances nAChR function in dendrites of MHb neurons. Nicotine 45-53 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 129-134 30867261-3 2019 Using an approach involving photoactivatable nicotine, we previously demonstrated that chronic nicotine (cNIC) potently enhances nAChR function in dendrites of MHb neurons. Nicotine 95-103 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 129-134 30867261-7 2019 Nicotine uncaging revealed nAChR functional enhancement by cNIC on proximal axonal membranes. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 27-32 30213668-9 2018 Nicotine (0.3 mg/kg) significantly improved initial reward learning in alpha7 WT and HT mice but did not improve learning in KO mice, suggesting an involvement of the alpha7 nAChR in the pro-learning effects of nicotine. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 167-179 30213668-9 2018 Nicotine (0.3 mg/kg) significantly improved initial reward learning in alpha7 WT and HT mice but did not improve learning in KO mice, suggesting an involvement of the alpha7 nAChR in the pro-learning effects of nicotine. Nicotine 211-219 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 167-179 30355112-3 2018 Nicotine"s interactions with vascular cell nicotinic acetylcholine receptors containing alpha7 subunits (alpha7*-nAChR) are thought to promote local inflammation and sustained angiogenesis. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 105-118 30355112-7 2018 Coexposure to an alpha7*-nAChR antagonist abolished nicotine"s deleterious effect. Nicotine 52-60 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 17-30 30355112-8 2018 In addition, nicotine"s promotion of aneurysm rupture was absent in smooth muscle cell-specific alpha7*-nAChR subunit knockout mice but not in mice lacking alpha7*-nAChR on endothelial cells or macrophages. Nicotine 13-21 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 96-109 30355112-10 2018 alpha7*-nAChR antagonist reversed nicotine-induced upregulation of these growth factors and cytokines. Nicotine 34-42 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 0-13 30355112-11 2018 Conclusions- Our findings indicate that nicotine exposure promotes aneurysmal rupture through actions on vascular smooth muscle cell alpha7*-nAChR. Nicotine 40-48 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 133-146 29059422-9 2018 Implications: Positive allosteric modulators of nAChR such as dFBr reduce nicotine withdrawal symptoms supporting the potential clinical use of this novel class of nAChR-based therapeutics as smoking cessation aid. Nicotine 74-82 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 48-53 29549391-1 2018 RATIONALE: Recent preclinical data has implicated the alpha7 nicotinic acetylcholine receptor (nAChR) as a target in modulating nicotine reward. Nicotine 128-136 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 95-100 29549391-2 2018 However, the role of the channel properties of the alpha7 nAChR in nicotine withdrawal is unknown. Nicotine 67-75 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 51-63 29549391-3 2018 OBJECTIVES: This study aimed to investigate the impact of alpha7 nAChR pharmacological modulation on mecamylamine-precipitated nicotine withdrawal behaviors in mice by using positive allosteric modulators (PAMs). Nicotine 127-135 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 58-70 29549391-8 2018 Nicotine withdrawal signs were precipitated upon administration of the non-selective nAChR antagonist mecamylamine (3.5 mg/kg, i.p.). Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 85-90 29549391-12 2018 CONCLUSIONS: Taken together, our results suggest that modulation of the alpha7 nAChR can play important roles in mecamylamine-precipitated nicotine withdrawal behaviors in mice. Nicotine 139-147 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 72-84 29549391-14 2018 These findings highlight a beneficial effect of using alpha7 nAChR PAMs in some aspects of precipitated nicotine withdrawal. Nicotine 104-112 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 61-66 29059422-9 2018 Implications: Positive allosteric modulators of nAChR such as dFBr reduce nicotine withdrawal symptoms supporting the potential clinical use of this novel class of nAChR-based therapeutics as smoking cessation aid. Nicotine 74-82 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 164-169 28585241-8 2018 Consistent with previous reports, the dose-dependent increase in nAChR in wild-type mice following chronic nicotine treatment, measured with any of the methods, reached a maximum. Nicotine 107-115 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 65-70 29266170-8 2018 Wheel running induced a significant up-regulation of alpha7 nAChR binding in the CA2/3 area of the hippocampus of nicotine-treated mice. Nicotine 114-122 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 60-65 29266170-10 2018 Nicotine withdrawal increased plasma corticosterone levels and alpha4beta2* nAChR binding, irrespective of exercise regimen. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 76-81 29671814-3 2018 In this study, we investigated whether varenicline, a partial &alpha;4&beta;2*nAChR agonist which reduces nicotine, alcohol and sucrose consumption, can reduce stress, a driving factor in substance use disorders. Nicotine 114-122 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 86-91 29114104-2 2018 In mice, nAChR activation by nicotine is anti-aggressive, or "serenic," an effect which requires alpha7 nAChRs and is recapitulated by GTS-21, an alpha7 nAChR partial agonist. Nicotine 29-37 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 104-109 29114104-10 2018 Short hairpin RNA knockdown of Chrna7 in the DG enhanced baseline aggression and eliminated the serenic effects of both nicotine and GTS-21 on attack latency. Nicotine 120-128 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 31-37 29791746-1 2018 Nicotine, acting through nicotinic acetylcholine receptors (nAChRs), increases the firing rate of both orexigenic agouti-related peptide (AgRP) and anorexigenic pro-opiomelanocortin (POMC) neurons in the arcuate nucleus of the hypothalamus (ARC), yet nicotine and other nAChR agonists decrease food intake in mice. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 60-65 29791746-1 2018 Nicotine, acting through nicotinic acetylcholine receptors (nAChRs), increases the firing rate of both orexigenic agouti-related peptide (AgRP) and anorexigenic pro-opiomelanocortin (POMC) neurons in the arcuate nucleus of the hypothalamus (ARC), yet nicotine and other nAChR agonists decrease food intake in mice. Nicotine 251-259 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 60-65 29114104-2 2018 In mice, nAChR activation by nicotine is anti-aggressive, or "serenic," an effect which requires alpha7 nAChRs and is recapitulated by GTS-21, an alpha7 nAChR partial agonist. Nicotine 29-37 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 9-14 29355641-2 2018 The nicotinic acetylcholine receptors (nAChRs) are critical for both alcohol and nicotine addiction mechanisms, since nAChR drugs that reduce nicotine consumption have been shown to also reduce alcohol consumption. Nicotine 81-89 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 39-44 29355641-2 2018 The nicotinic acetylcholine receptors (nAChRs) are critical for both alcohol and nicotine addiction mechanisms, since nAChR drugs that reduce nicotine consumption have been shown to also reduce alcohol consumption. Nicotine 142-150 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 39-44 29206881-1 2017 The alpha6 nicotinic acetylcholine receptor (nAChR) subunit is an attractive drug target for treating nicotine addiction because it is present at limited sites in the brain including the reward pathway. Nicotine 102-110 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 45-50 29054611-8 2018 In contrast, all groups presented a nicotine-evoked nAChR upregulation in the cerebral cortex. Nicotine 36-44 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 52-57 29293602-3 2018 This indicates that nicotine evokes bitter taste by activating a Trpm5-dependent pathway and a Trpm5-independent but nAChR-dependent pathway. Nicotine 20-28 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 117-122 29293602-13 2018 We conclude that nAChR subunits are expressed in Trpm5-positive TRCs and their expression levels are differentially altered by chronic oral exposure to nicotine and ethanol. Nicotine 152-160 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 17-22 29272360-0 2018 alpha7-Nicotinic Acetylcholine Receptor Agonist Ameliorates Nicotine Plus High-Fat Diet-Induced Hepatic Steatosis in Male Mice by Inhibiting Oxidative Stress and Stimulating AMPK Signaling. Nicotine 60-68 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 0-39 29272360-7 2018 We conclude that the alpha7nAChR agonist PNU protects against nicotine plus HFD-induced hepatic steatosis in obese mice. Nicotine 62-70 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 21-32 28809075-4 2018 In addition, the antinociceptive properties of nicotine, a non-selective nAChR agonist with a high affinity for alpha4beta2 nAChRs, is well-known. Nicotine 47-55 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 73-78 29206881-5 2017 Lynx1 removal reduced the alpha6 component of nicotine-mediated rubidium efflux and dopamine (DA) release from synaptosomal preparations with no effect on numbers of alpha6beta2 binding sites, indicating that lynx1 is functionally important for alpha6* nAChR activity. Nicotine 46-54 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 245-258 29117258-2 2017 One explanation for the variability and delay in disease onset is that nicotine, the addictive component of CS, acts through the ionotropic nicotinic acetylcholine receptor (nAChR) alpha7 (alpha7) to modulate anti-inflammatory protection. Nicotine 71-79 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 140-172 29117258-2 2017 One explanation for the variability and delay in disease onset is that nicotine, the addictive component of CS, acts through the ionotropic nicotinic acetylcholine receptor (nAChR) alpha7 (alpha7) to modulate anti-inflammatory protection. Nicotine 71-79 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 174-179 28700952-0 2017 Nicotine facilitates nicotinic acetylcholine receptor targeting to mitochondria but makes them less susceptible to selective ligands. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 21-53 28401925-0 2017 Menthol Enhances Nicotine Reward-Related Behavior by Potentiating Nicotine-Induced Changes in nAChR Function, nAChR Upregulation, and DA Neuron Excitability. Nicotine 17-25 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 94-99 28401925-0 2017 Menthol Enhances Nicotine Reward-Related Behavior by Potentiating Nicotine-Induced Changes in nAChR Function, nAChR Upregulation, and DA Neuron Excitability. Nicotine 17-25 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 110-115 28401925-0 2017 Menthol Enhances Nicotine Reward-Related Behavior by Potentiating Nicotine-Induced Changes in nAChR Function, nAChR Upregulation, and DA Neuron Excitability. Nicotine 66-74 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 94-99 28401925-0 2017 Menthol Enhances Nicotine Reward-Related Behavior by Potentiating Nicotine-Induced Changes in nAChR Function, nAChR Upregulation, and DA Neuron Excitability. Nicotine 66-74 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 110-115 28401925-4 2017 Menthol plus nicotine upregulates nAChR number and function on midbrain DA neurons more than nicotine alone. Nicotine 13-21 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 34-39 29114204-3 2017 Effects of ethanol on specific brain nAChR subtypes within the mesolimbic dopaminergic (DA) pathway may be a key element in the comorbidity of ethanol and nicotine. Nicotine 155-163 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 37-42 29088845-0 2017 Nicotine suppresses apoptosis by regulating alpha7nAChR/Prx1 axis in oral precancerous lesions. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 44-55 29212186-0 2017 alpha7 nAChR mediated Fas demethylation contributes to prenatal nicotine exposure-induced programmed thymocyte apoptosis in mice. Nicotine 64-72 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 0-12 29212186-4 2017 Further, by exposing thymocytes to 0-100 muM of nicotine in vitro for 48 h, we found that nicotine increased alpha7 nicotinic acetylcholine receptor (nAChR) expression, activated the Fas apoptotic pathway, and promoted thymocyte apoptosis in concentration-dependent manners. Nicotine 48-56 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 150-155 29212186-4 2017 Further, by exposing thymocytes to 0-100 muM of nicotine in vitro for 48 h, we found that nicotine increased alpha7 nicotinic acetylcholine receptor (nAChR) expression, activated the Fas apoptotic pathway, and promoted thymocyte apoptosis in concentration-dependent manners. Nicotine 90-98 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 150-155 29212186-6 2017 Moreover, the alpha7 nAChR specific antagonist alpha-bungarotoxin can abrogate nicotine-induced TET2 increase, and the following Fas demethylation and Fas-mediated apoptosis. Nicotine 79-87 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 21-26 29018331-7 2017 Nicotine exposure is protective against directly-induced EAE in WT or alpha7/alpha9 DKO animals relative to effects seen in WT/vehicle-treated mice, but, remarkably, EAE is exacerbated in vehicle-treated alpha7/alpha9 DKO mice. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 70-76 29018331-7 2017 Nicotine exposure is protective against directly-induced EAE in WT or alpha7/alpha9 DKO animals relative to effects seen in WT/vehicle-treated mice, but, remarkably, EAE is exacerbated in vehicle-treated alpha7/alpha9 DKO mice. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 204-210 28928157-8 2017 Furthermore nicotine treatment suppressed NF-kappaB activation in lipopolysaccharide-stimulated RAW264.7 cells, and alpha-bungarotoxin (an alpha7-nAChR selective antagonist) partly inhibited the nicotine-treatment effect. Nicotine 195-203 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 139-151 28551099-6 2017 In the in vivo study, alpha7-nAChR knockout (alpha7-KO) reversed the beneficial effects of nicotine on motor deficits, dopaminergic neuron loss, astrocyte and microglia activation, and reduced striatal dopamine release induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Nicotine 91-99 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 22-34 28551099-7 2017 Injury to SH-SY5Y cells by 1-methyl-4-phenylpyridinium treatment was also ameliorated by nicotine, and this effect was abolished by methyllycaconitine (MLA), a selective alpha7-nAChR antagonist, or by siRNA-mediated alpha7-nAChR knockdown. Nicotine 89-97 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 170-182 29088845-4 2017 In DOK cells, Prx1 knockdown and blocking alpha7nAChR activated apoptosis, and nicotine increased the expression of Prx1, alpha3nAChR and alpha7nAChR, and inhibited MAPK activation. Nicotine 79-87 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 138-149 29088845-5 2017 Moreover, nicotine suppressed apoptosis depending on Prx1 and alpha7nAChR in DOK cells. Nicotine 10-18 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 62-73 29088845-8 2017 Our data demonstrate that nicotine inhibits cell apoptosis and promotes the growth of oral precancerous lesions via regulating alpha7nAChR/Prx1 during carcinogenesis of OSCC. Nicotine 26-34 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 127-138 28700952-3 2017 Nicotine has been shown to favor nAChR pentamer assembly, folding, and maturation on the way of biosynthesis. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 33-38 28700952-8 2017 It was found that nicotine consumption increased the ratio of mitochondrial vs non-mitochondrial nAChRs in the liver, enhanced fucosylation of mitochondrial nAChRs, but prevented the binding of alpha-cobratoxin and the cytochrome c release-attenuating effects of nAChR-specific agonists, antagonists, or positive allosteric modulators. Nicotine 18-26 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 97-102 28700952-9 2017 It is concluded that nicotine consumption in vivo favors nAChR glycosylation and trafficking to mitochondria but makes them less susceptible to the effects of specific ligands. Nicotine 21-29 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 57-62 28759616-9 2017 These results reveal that attenuation of alpha4* nAChR function in reward-related brain circuitry of adult animals may increase nicotine intake by enhancing the rewarding effects and/or reducing the aversive effects of nicotine. Nicotine 128-136 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 41-54 28759616-9 2017 These results reveal that attenuation of alpha4* nAChR function in reward-related brain circuitry of adult animals may increase nicotine intake by enhancing the rewarding effects and/or reducing the aversive effects of nicotine. Nicotine 219-227 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 41-54 28347687-11 2017 These data provide novel evidence about the effects of chronic nicotine inhalation on the expression of key glial glutamate transporters as well as alpha-7 nAChR. Nicotine 63-71 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 148-161 28347687-0 2017 Effects of chronic inhalation of electronic cigarettes containing nicotine on glial glutamate transporters and alpha-7 nicotinic acetylcholine receptor in female CD-1 mice. Nicotine 66-74 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 111-151 28498560-6 2017 These effects phenocopy those observed after dopamine receptor antagonism, but are not additive, suggesting that alpha5 nAChR subunits act in the same pathway as dopamine and are critical for the experience of nicotine"s aversive, but not rewarding motivational effects in both a nondependent and nicotine-dependent and -withdrawn motivational state. Nicotine 210-218 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 120-125 28498560-2 2017 Genetic deletion of alpha5 nicotinic acetylcholine receptor (nAChR) subunits has been associated with increased nicotine intake, however, it remains unclear whether acute nicotine is less aversive or more rewarding, and whether mice lacking the alpha5 nAChR subunit can experience withdrawal from chronic nicotine. Nicotine 112-120 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 61-66 28498560-6 2017 These effects phenocopy those observed after dopamine receptor antagonism, but are not additive, suggesting that alpha5 nAChR subunits act in the same pathway as dopamine and are critical for the experience of nicotine"s aversive, but not rewarding motivational effects in both a nondependent and nicotine-dependent and -withdrawn motivational state. Nicotine 297-305 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 120-125 28315314-4 2017 The predominant subunit responsible for nicotine-mediated proliferation in normal and cancer cells, the alpha7 nicotinic acetylcholine receptor (alpha7-nAChR), was more highly expressed in human cholangiocarcinoma cell lines compared with normal human cholangiocytes. Nicotine 40-48 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 145-157 28279662-4 2017 Activation of the homomeric alpha7 nAChR reduces nicotine"s rewarding properties in conditioned place preference (CPP) test and i.v. Nicotine 49-57 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 28-40 28279662-7 2017 The present study investigated PPARalpha as a possible mediator of the effect of alpha7 nAChR activation in nicotine dependence. Nicotine 108-116 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 81-93 28279662-8 2017 Our results demonstrate the PPARalpha antagonist GW6471 blocks actions of the alpha7 nAChR agonist PNU282987 on nicotine reward in an unbiased CPP test in male ICR adult mice. Nicotine 112-120 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 78-90 28279662-9 2017 These findings suggests that alpha7 nAChR activation attenuates nicotine CPP in a PPARalpha-dependent manner. Nicotine 64-72 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 29-41 28315314-5 2017 Nicotine also stimulated the proliferation of cholangiocarcinoma cell lines and promoted alpha7-nAChR-dependent activation of proliferation and phosphorylation of extracellular-regulated kinase in Mz-ChA-1 cells. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 89-101 28315314-6 2017 In addition, nicotine and PNU282987 (alpha7-nAChR agonist) accelerated the growth of the cholangiocarcinoma tumors in our xenograft mouse model and increased fibrosis, proliferation of the tumor cells, and phosphorylation of extracellular-regulated kinase activation. Nicotine 13-21 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 37-49 28315314-8 2017 Taken together, results of this study suggest that nicotine acts through alpha7-nAChR and plays a novel role in the pathogenesis of cholangiocarcinoma. Nicotine 51-59 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 73-85 28187919-10 2017 Taken together these data first demonstrate that a D3R-nAChR heteromer is present in DA neurons and represents the functional unit mediating the neurotrophic effects of nicotine. Nicotine 169-177 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 55-60 28243714-0 2017 Nicotine withdrawal-induced inattention is absent in alpha7 nAChR knockout mice. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 53-65 28243714-6 2017 Experiment 2 used 14 and 40 mg kg-1 day-1 nicotine treatment in alpha7 nAChR knockout (KO) and wildtype (WT) littermates tested 4 h after pump removal. Nicotine 42-50 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 71-76 28243714-11 2017 CONCLUSIONS: The alpha7 nAChR may underlie nicotine withdrawal-induced deficits in target detection but is not required for response disinhibition deficits. Nicotine 43-51 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 17-29 28349965-6 2017 Administration of nicotine, an alpha7nAchR ligand, to wild-type mice increased serum RANKL levels. Nicotine 18-26 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 31-42 28013195-10 2017 Stimulation of neutrophils with an alpha7-specific nAChR agonist induced NETosis, whereas pretreatment with an nAChR antagonist attenuated nicotine-induced NETosis. Nicotine 139-147 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 111-116 28112735-6 2017 Two-photon calcium imaging in awake mouse models showed that nicotine can differentially influence PFC pyramidal cell activity by nAChR modulation of layer II/III hierarchical inhibitory circuits. Nicotine 61-69 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 130-135 28332590-8 2017 Finally, we showed that nicotine-induced modifications of alcohol responses were absent in beta2-/- and beta4-/- mice, suggesting that nicotine triggers beta2* and beta4 * nAChR-dependent neuroadaptations that subsequently modify the responses to alcohol and thus indicating these receptors as key mediators in the complex interactions between these two drugs. Nicotine 24-32 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 172-177 28332590-8 2017 Finally, we showed that nicotine-induced modifications of alcohol responses were absent in beta2-/- and beta4-/- mice, suggesting that nicotine triggers beta2* and beta4 * nAChR-dependent neuroadaptations that subsequently modify the responses to alcohol and thus indicating these receptors as key mediators in the complex interactions between these two drugs. Nicotine 135-143 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 172-177 28028600-11 2017 CONCLUSIONS: These results suggest that alpha4beta2* nAChRs differentially mediate the discriminative stimulus effects of nicotine and varenicline, and suggest that varenicline has substantial non-alpha4beta2 nAChR activity. Nicotine 122-130 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 53-58 28074940-7 2017 These pathogenicities were significantly reduced by MLA, suggesting that alpha7 nAChR may play an important role in neuropathology caused by gp120, METH and NT, which are the major pathogenic factors contributing to the pathogenesis of HAND. Nicotine 157-159 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 73-85 28074940-2 2017 Here, we hypothesized that Glycoprotein 120 (gp120), methamphetamine (METH) and nicotine (NT) can enhance amyloid-beta (Abeta) accumulation in BMEC through Alpha7 nicotinic acetylcholine receptor (alpha7 nAChR). Nicotine 80-88 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 197-209 28074940-2 2017 Here, we hypothesized that Glycoprotein 120 (gp120), methamphetamine (METH) and nicotine (NT) can enhance amyloid-beta (Abeta) accumulation in BMEC through Alpha7 nicotinic acetylcholine receptor (alpha7 nAChR). Nicotine 90-92 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 197-209 28197102-7 2017 These results indicate that vagal nerve plays an important role in mediating the anti-inflammatory effect in viral myocarditis, and that cholinergic stimulation with nicotine also plays its peripheral anti-inflammatory role relying on alpha7nAChR, without requirement for the integrity of vagal nerve in the model. Nicotine 166-174 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 235-246 29348704-9 2017 Treatment with alpha7-nAChR agonist inhibits nicotine-induced upregulation of MMP and inflammatory cytokines through modulating ERK1/2/AP-1 signaling in RAW264.7 cells and AP-1 in MOVAS cells, providing a new therapeutic for abdominal aortic aneurysm. Nicotine 45-53 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 15-27 27793780-5 2017 The action of nicotine was blocked by 1muM dihydro-beta-erythroidine (DHbetaE; specific for alpha4* nAChRs), but not 10nM methyllycaconitine (MLA; specific for alpha7* nAChRs). Nicotine 14-22 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 160-166 27596561-8 2016 These results demonstrate the existence of diverse functional nAChR subtypes at presynaptic and postsynaptic sites in LHb, through which nicotine could facilitate or inhibit LHb neuronal activity and thus contribute to nicotine aversion or reward. Nicotine 137-145 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 62-67 27638450-8 2016 Interestingly, these nocifensive behavior alterations and differential responses to nicotine antinociceptive effects in BTBR mice were associated with significant downregulation of alpha3, alpha4, alpha5, alpha7, beta2, beta3, and beta4 nAChR subunits in several cerebral regions both, during embryonic development and adulthood. Nicotine 84-92 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 237-242 27378334-0 2016 Impairment of contextual fear extinction by chronic nicotine and withdrawal from chronic nicotine is associated with hippocampal nAChR upregulation. Nicotine 52-60 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 129-134 27378334-0 2016 Impairment of contextual fear extinction by chronic nicotine and withdrawal from chronic nicotine is associated with hippocampal nAChR upregulation. Nicotine 89-97 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 129-134 27378334-8 2016 However, it was also observed that the effects of prior chronic nicotine disappeared after 72 h in withdrawal, a timeline that closely matches with the timing of the chronic nicotine-induced upregulation of hippocampal nicotinic acetylcholine receptor (nAChR) density. Nicotine 64-72 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 219-251 27378334-8 2016 However, it was also observed that the effects of prior chronic nicotine disappeared after 72 h in withdrawal, a timeline that closely matches with the timing of the chronic nicotine-induced upregulation of hippocampal nicotinic acetylcholine receptor (nAChR) density. Nicotine 64-72 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 253-258 27378334-8 2016 However, it was also observed that the effects of prior chronic nicotine disappeared after 72 h in withdrawal, a timeline that closely matches with the timing of the chronic nicotine-induced upregulation of hippocampal nicotinic acetylcholine receptor (nAChR) density. Nicotine 174-182 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 219-251 27378334-8 2016 However, it was also observed that the effects of prior chronic nicotine disappeared after 72 h in withdrawal, a timeline that closely matches with the timing of the chronic nicotine-induced upregulation of hippocampal nicotinic acetylcholine receptor (nAChR) density. Nicotine 174-182 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 253-258 27238974-7 2016 Mecamylamine and the alpha4beta2 nAChR antagonist dihydro-beta-erythroidine, but not the alpha7 antagonist methyllycaconitine, antagonized the hypothermic effects of nicotine. Nicotine 166-174 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 33-38 27596561-8 2016 These results demonstrate the existence of diverse functional nAChR subtypes at presynaptic and postsynaptic sites in LHb, through which nicotine could facilitate or inhibit LHb neuronal activity and thus contribute to nicotine aversion or reward. Nicotine 219-227 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 62-67 27385416-14 2016 CONCLUSIONS: We propose that altered alpha5*-nAChR cholinergic signalling contributes to emotional/behavioural impairments that may be alleviated by nicotine consumption. Nicotine 149-157 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 45-50 27157710-1 2016 Studies with heterologous expression systems have shown that the alpha4beta2 nicotinic acetylcholine receptor (nAChR) subtype can exist in two stoichiometries (with two [(alpha4)2(beta2)3] or three [(alpha4)3(beta2)2] copies of the alpha subunit in the receptor pentamer) which have different pharmacological and functional properties and are differently regulated by chronic nicotine treatment. Nicotine 376-384 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 111-116 27157710-2 2016 However, the effects of nicotine treatment in vivo on native alpha4beta2 nAChR stoichiometry are not well known. Nicotine 24-32 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 73-78 27157710-8 2016 These data suggest that chronic nicotine exposure in vivo favors increased assembly of alpha4beta2 nAChR containing three beta2 subunits. Nicotine 32-40 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 99-104 26965141-5 2016 Neutrophils of female mice after chronic nicotine consumption acquired sensitivity to nAChR agonists. Nicotine 41-49 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 86-91 27559543-4 2016 We observed significant effects of nicotine exposure on the beta2*-nAChR-associated proteome in human and mouse cortex, particularly in the abundance of the nAChR subunits themselves, as well as putative interacting proteins that make up core components of neuronal excitability (Na/K ATPase subunits), presynaptic neurotransmitter release (syntaxins, SNAP25, synaptotagmin), and a member of a known nAChR protein chaperone family (14-3-3zeta). Nicotine 35-43 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 157-162 26471256-3 2016 Clinical studies also suggest that abnormalities in cholinergic signaling are associated with major depressive disorder, whereas pre-clinical studies have implicated both beta2 subunit-containing (beta2*) and alpha7 nAChRs in the effects of nicotine in models of anxiety- and depression-like behaviors. Nicotine 241-249 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 209-215 27228072-5 2016 Treatment of cells with nicotine induced the mRNA and protein levels of alpha7 nAChR; this could be abrogated by treatment with inhibitors targeting Src, PI3K, MEK, alpha7 nAChR, CDK4/6 or a disruptor of the Rb-Raf-1 interaction. Nicotine 24-32 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 165-177 27228072-6 2016 Further, nicotine-mediated induction of alpha7 nAChR was reduced when E2F1 was depleted and in contrast elevated when STAT1 was depleted by siRNAs. Nicotine 9-17 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 40-52 27228072-8 2016 These results suggest an autoregulatory feed-forward loop that induces the levels of alpha7 nAChR upon exposure to nicotine, which enhances the strength of the signal. Nicotine 115-123 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 85-97 27228072-9 2016 It can be imagined that such an induction of alpha7 nAChR contributes to the tumor-promoting functions of nicotine. Nicotine 106-114 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 45-57 26921469-15 2016 These results demonstrate that striatal cholinergic interneurons play a critical role in LIDs and support the idea that nicotine treatment reduces LIDs via nAChR desensitization. Nicotine 120-128 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 156-161 27068812-7 2016 Nicotine-induced currents were obtained in neurons from alpha7, beta2, alpha5, and alpha6 knockout mice. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 56-62 26585290-1 2016 Nicotine exerts its psychopharmacological effects by activating the nicotinic acetylcholine receptor (nAChR), composed of alpha and/or beta subunits, giving rise to a diverse population of receptors with a distinct pharmacology. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 68-100 26585290-1 2016 Nicotine exerts its psychopharmacological effects by activating the nicotinic acetylcholine receptor (nAChR), composed of alpha and/or beta subunits, giving rise to a diverse population of receptors with a distinct pharmacology. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 102-107 27228072-3 2016 This nicotine-mediated tumor progression is facilitated through activation of nicotinic acetylcholine receptors (nAChRs), specifically the alpha7 subunit; however, how the alpha7 nAChR gene is regulated in lung adenocarcinoma is not fully clear. Nicotine 5-13 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 172-184 27228072-5 2016 Treatment of cells with nicotine induced the mRNA and protein levels of alpha7 nAChR; this could be abrogated by treatment with inhibitors targeting Src, PI3K, MEK, alpha7 nAChR, CDK4/6 or a disruptor of the Rb-Raf-1 interaction. Nicotine 24-32 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 72-84 26428091-0 2016 Exposure to nicotine increases nicotinic acetylcholine receptor density in the reward pathway and binge ethanol consumption in C57BL/6J adolescent female mice. Nicotine 12-20 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 31-63 26428091-3 2016 Past studies report that nicotine and ethanol activate dopamine neurons in the reward pathway and may increase synaptic levels of dopamine in the nucleus accumbens through nicotinic acetylcholine receptor (nAChR) stimulation. Nicotine 25-33 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 172-204 26428091-3 2016 Past studies report that nicotine and ethanol activate dopamine neurons in the reward pathway and may increase synaptic levels of dopamine in the nucleus accumbens through nicotinic acetylcholine receptor (nAChR) stimulation. Nicotine 25-33 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 206-211 26428091-9 2016 Autoradiographic analysis of nAChR density revealed higher epibatidine binding in frontal cortical regions in mice exposed to nicotine and ethanol compared to mice exposed to ethanol only. Nicotine 126-134 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 29-34 26786889-7 2016 These results suggest that nicotine inhibits the expression of TSLP by suppressing the activation of NF-kappaB through the alpha7 nAChR-PI3K-AMPK signaling pathway. Nicotine 27-35 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 123-135 26786889-5 2016 Nicotine inhibition of TSLP production was abolished by pretreatments with alpha7 nicotinic acetylcholine receptor (alpha7 nAChR) antagonists, AMP-activated protein kinase (AMPK) inhibitor, and phosphoinositide 3-kinase (PI3K) inhibitors. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 75-114 26786889-5 2016 Nicotine inhibition of TSLP production was abolished by pretreatments with alpha7 nicotinic acetylcholine receptor (alpha7 nAChR) antagonists, AMP-activated protein kinase (AMPK) inhibitor, and phosphoinositide 3-kinase (PI3K) inhibitors. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 116-128 26851533-3 2016 This study was therefore designed to examine the effects of cholinergic stimulation with alpha7-nAChR agonist nicotine in a murine model of acute viral myocarditis. Nicotine 110-118 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 89-101 25363563-2 2016 One possible mechanism underlying this higher addiction liability is an ontogenetically differential cellular response induced by nicotine in neurons mediating the reinforcing or euphoric effects of this drug, which could arise from age-related differences in the composition of nicotinic acetylcholine receptor (nAChR) subunits. Nicotine 130-138 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 279-311 25363563-2 2016 One possible mechanism underlying this higher addiction liability is an ontogenetically differential cellular response induced by nicotine in neurons mediating the reinforcing or euphoric effects of this drug, which could arise from age-related differences in the composition of nicotinic acetylcholine receptor (nAChR) subunits. Nicotine 130-138 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 313-318 26397391-4 2015 Treatment with the alpha7 nAChR agonist nicotine for three weeks obviously attenuated hepatic steatosis in a high-fat diet-induced mouse model of NASH. Nicotine 40-48 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 19-31 26746805-2 2016 Nicotine, the major neurotoxic component of cigarette smoke, induces its actions by binding to nicotinic acetylcholine receptors (nAChR), with one downstream effect being increased apoptosis. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 95-128 26746805-2 2016 Nicotine, the major neurotoxic component of cigarette smoke, induces its actions by binding to nicotinic acetylcholine receptors (nAChR), with one downstream effect being increased apoptosis. Nicotine 0-8 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 130-135 26192545-1 2015 INTRODUCTION: Chronic treatment with nicotine is known to increase the alpha4beta2-nAChR sites in brain, to decrease alpha6beta2-nAChR sites and to have minimal effect on alpha3beta4-and alpha7-nAChR populations. Nicotine 37-45 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 83-88 26192545-1 2015 INTRODUCTION: Chronic treatment with nicotine is known to increase the alpha4beta2-nAChR sites in brain, to decrease alpha6beta2-nAChR sites and to have minimal effect on alpha3beta4-and alpha7-nAChR populations. Nicotine 37-45 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 129-134 26192545-1 2015 INTRODUCTION: Chronic treatment with nicotine is known to increase the alpha4beta2-nAChR sites in brain, to decrease alpha6beta2-nAChR sites and to have minimal effect on alpha3beta4-and alpha7-nAChR populations. Nicotine 37-45 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 187-199 26688111-2 2016 Although there is also strong evidence showing that the acute nicotine"s enhancing effects on contextual fear conditioning require high-affinity alpha4beta2 nicotinic acetylcholine receptors (nAChRs), it is unknown which nAChR subtypes are involved in the acute nicotine-induced impairment of contextual fear extinction. Nicotine 62-70 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 192-197 26740650-11 2016 Thus, nicotine, at a concentration too low to activate an appreciable fraction of plasma membrane nAChRs, induces two sequelae of pharmacological chaperoning in the ER: UPR suppression and nAChR upregulation. Nicotine 6-14 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 98-103 26631628-6 2016 The extent of nicotine-induced nAChR up-regulation, and the time course of its reversal were comparable in all three areas. Nicotine 14-22 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 31-36 26397391-7 2015 In addition, the present study showed that nicotine-stimulated alpha7 nAChR activation led to a significant downregulation of nuclear factor kappa B (NK-kappaB) and extracellular signal-regulated kinase (ERK). Nicotine 43-51 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 63-75 25616906-10 2015 A alpha7nAChR antagonist abrogated the anti-inflammatory effects of nicotine and suppressed STAT3 activity. Nicotine 68-76 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 8-13 26212554-2 2015 Multiple models of aggression across species suggest that the nicotinic acetylcholine receptor (nAChR) agonist nicotine has anti-aggressive (serenic) properties. Nicotine 111-119 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 62-94 26212554-2 2015 Multiple models of aggression across species suggest that the nicotinic acetylcholine receptor (nAChR) agonist nicotine has anti-aggressive (serenic) properties. Nicotine 111-119 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 96-101 26212554-9 2015 Furthermore, pharmacological studies suggest that activation of alpha7 nAChRs underlies the serenic effects of nicotine. Nicotine 111-119 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 64-70 26096224-3 2015 METHODS: The alpha-7 nicotinic acetylcholine receptor (alpha7nAChR) was stimulated with AR-R17779 or nicotine in NOD mice. Nicotine 101-109 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 13-53 26096224-3 2015 METHODS: The alpha-7 nicotinic acetylcholine receptor (alpha7nAChR) was stimulated with AR-R17779 or nicotine in NOD mice. Nicotine 101-109 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 55-66 26507386-2 2015 The aim of this study was to investigate the dose-related effects of nicotine, an alpha7 nAChR agonist, in murine model of viral myocarditis. Nicotine 69-77 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 82-94